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ABSTRACT
Dissociable Antibody Microarray (DAMA) staining is a novel technique that integrates
protein microarrays with conventional immunostaining techniques. It can simultaneously
determine the expression and subcellular localizations (SCLs) of hundreds of proteins in cultured
cells. I optimized this technology for protein expression and SCL profiling, and generated
expression profile data analysis program DAMAPEP, molecular image database management
program ChipView and automatic SCL assignment program DAMASCL.
We demonstrated the application of this technique in the identification of potential
biomarkers for breast cancer. We compared the expression profiles of 312 proteins among ten
breast cell lines and identified 10 differentially expressed proteins. Among those proteins,
RAIDD, Rb p107, Rb p130, SRF and Tyk2 were confirmed by western blot and statistical
analysis to have higher expression levels in cancer breast cells than in normal breast cells. We
also compared the SCL profiles of 325 proteins among nine breast cell lines, and identified one
protein, Cyclin B1, with different SCLs between two normal and seven cancer breast cell lines.
With individual immunostaining, Cyclin B1 was confirmed to localize in the cytoplasm of seven
cancer cells and in both cytoplasm and nuclei of two normal cells and to have higher expression
levels in the seven cancer cell lines.
We expanded the scale of DAMA staining to include 400 antibodies per array and surveyed
SCL profiles of 400 antibodies in five prostate cell lines. Five proteins were identified to have
altered SCL patterns between normal and cancer prostate cell lines. GRK2 was so far confirmed
to localize ubiquitously in the cytosol of three normal and one cancer prostate cell lines while
concentrating at certain regions right beneath plasma membrane in the other two cancer prostate
cell lines. We also extended the application of DAMA staining to interrogate protein expression
profiles in tissue samples and found 3 proteins with differential expression in two tissue samples
vii

from different breast cancer patients, demonstrating the potential use of DAMA staining in
carcinoma characterization and classification. Database of annotated protein molecular images
obtained from DAMA staining need to be created and shared for better understanding of cancer
biology.
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CHAPTER ONE:
GENERAL INTRODUCTION
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Introduction
Cancer is a major public health problem in the United States and many other developed
countries of the world. In the United States, one in 4 deaths can be attributed to cancer (Jemal et
al. 2008). Human cancers involve the complex interplay among genetic, transcriptional,
translational and post-translational alterations. Comprehensive understanding of the biology of
cancer requires the identification of all these alterations and the molecular pathways causing
them. Particularly, comparative analysis of these alterations between normal cells and tumors
will lead to identification of molecular markers for early cancer detection and effective
molecule-targeted prevention and treatments.
Traditional methods have been contributing to the discovery and elucidation of many of
these alterations by carrying out one experiment at a time. Powerful as they are, these methods
are usually time consuming and labor intensive in order to obtain a global view. In the past two
decades, high throughput approaches have been developed and used to explore and study
genomic and proteomic molecular changes for the understanding of cancer. Large scale DNA
sequencing technology has accelerated the completion of Human Genome Project (Lander et al.
2001; Venter et al. 2001; Consortium 2004) and many others (Liolios et al. 2008). With the
accumulation of genomic sequence information, the scientific focus is shifting to the
development of methods that can efficiently utilize this wealth of information. Nucleic acid
microarrays in particular have revolutionized genetic research, enabling the exploration of both
genetic and transcriptional alterations on the global scale. Protein microarrays are also of high
interest and have proved to be versatile and powerful in studying protein expression, protein
modification and protein interaction networks on a grand scale.
This dissertation describes the further development of one staining technique which
combines a novel platform of protein microarray called dissociable antibody microarray (DAMA)
2

with immunostaining, and its application in protein expression and subcellular localization (SCL)
profiling of breast cancer cell lines for potential biomarker discovery. This chapter overviews the
literature of approaches for systematic study of protein functions with emphasis on microarray
technology. Chapter 2 describes the application of DAMA staining in profiling protein
expression in breast cancer cell lines. Chapter 3 describes the optimization and development of
DAMA staining in obtaining SCL profiles of breast cancer cell lines. Other extensions and
applications of this technique in prostate cancer cell lines and breast cancer tissue samples are
summarized in Chapter 4. Chapter 5 provides a general discussion of this technique.

Systematic Study of Protein Functions
Proteins play essential roles in life and they are involved in a variety of processes and
constitute the functional and structural elements of a cell. Proteins can act as building blocks,
enzymes, transporters, storage molecules, growth regulators, and antibodies. The term proteome,
a word consisting of proteins and genome, was originally coined to describe the complete set of
proteins expressed by a genome (Wasinger et al. 1995). While genomes are relatively static over
time and almost all cell or tissue types of the same organism share the same composition, the
proteome of an organism is highly dynamic. Each tissue or cell type expresses only a subset of
the proteome. Even in the same cell type, the levels of expressed proteins are always fluctuating
and regulated by state of development and surrounding environment.
One of the most challenging tasks in biological and biomedical research is to systematically
characterize the proteomes of various organisms. The ultimate goal of this immense task is to
explore and quantify the composition of the proteomes and comprehensively understand the
functions of all proteins. Protein functions may be determined in four interrelated aspects:
expression, modifications, SCL and interaction partners. Here, some important approaches for
systematically exploring protein expression and SCLs are reviewed.
3

Protein Expression Profiling
Protein expression is a tightly regulated process. Assuming that only a single representative
protein is produced from every gene locus, the number of protein-coding genes in humans is
predicted to be 22,740 (Flicek et al. 2008). However, the actual number of protein species is still
not known due to the fact that different protein isoforms exist as a result of mechanisms such as
alternative splicing and post-translational modifications. Specific sets of proteins are expressed
in different tissue and cell types. Expression profiling is to investigate what protein species are
present under given conditions in a defined sample, and their abundance. Therefore, systematic
expression analysis involves two aspects: identification and quantification of expressed proteins.
The strategies to explore protein expression can roughly be divided into two categories:
separation-based and probe-based strategies. The separation-based expression explorations
involve a range of sophisticated technologies to separate and detect the proteins of very different
and also of very similar biochemical properties. One of the most commonly used large-scale
separation technologies for proteins is the two-dimensional gel electrophoresis. Introduced in the
mid-1970s (O'Farrell 1975), two-dimensional sodium dodecyl-sulfate polyacrylamide gel
electrophoresis (2D-SDS-PAGE) has been a widely used routine for separation of proteins from
complex mixtures (Falk et al. 2007). 2D-SDS-PAGE couples isoelectric focusing in the first
dimension with SDS-PAGE in the second dimension, enabling separation of proteins according
to their isoelectric points and molecular weights. With current settings, over 5000 protein spots
can be resolved on gel in a single experiment, and the detecting limit is about 1 ng protein (Gorg
et al. 2004).
The next step after separation of proteins with 2D-PAGE is to determine the identity of the
resolved proteins. For this purpose, mass spectrometry (MS) can be employed. Spots of interest
on the 2D-SDS-PAGE gel are extracted and enzymatically digested. The resulting peptides from
4

digestion are subjected to ionization. There are several approaches to volatize and ionize the
peptides. The two main approaches used for MS protein identification are electrospray ionization
(ESI) (Fenn et al. 1989) and matrix-assisted laser desorption/ionization (MALDI) (Karas and
Hillenkamp 1988). With ESI the peptides are ionized directly from a solution, while with
MALDI the samples are mixed with a matrix compound and ionized using laser pulses. The
volatized ions then pass through a mass analyzer which measures their mass to charge ratio (m/z).
A detector registers the number of ions at each m/z value. The obtained mass spectra of the
peptide can then be matched against available protein databases with bioinformatics tools to
estimate the probability that the peptide mass spectra originates from a certain protein.
Probe-based strategy for exploring protein expression utilizes the specific binding of probes
with their targets. One of the most commonly used probes or affinity reagents is antibodies, the
key components of the adaptive immune system. Conventional approaches using antibodies to
study protein expression include western blotting, immunohistochemistry (IHC), and
enzyme-linked immunosorbent assay (ELISA). Western blotting is usually used to detect a
protein of interest in a protein lysate extracted from a cell or tissue sample. The lysate is first
subjected to gel electrophoresis, typically SDS-PAGE, so that proteins are separated according to
their molecular weights only. The proteins are then transferred from gel to a membrane, on
which the protein of interest is probed with a specific antibody and visualized (Burnette 1981).
With the molecular weight of a protein known, western blotting can be used to measure relative
amounts of proteins present in different samples as they can be run in parallel on the same gel.
IHC provides information on the expression and localization of a protein inside the cell or tissue,
and has therefore become the standard method to evaluate protein expression in situ
(Ramos-Vara 2005). In a typical IHC assay, an antibody is applied to fixed tissue or cell sample
to bind to its antigen. The bound antibody is then detected with color-producing reactions to
5

determine the expression level and SCL of the antigen, usually by fluorescence microscopy.
ELISA has been the most commonly used method for protein quantification (Lequin 2005). In a
typical ELISA, the sample with an unknown amount of antigen is immobilized on a solid support.
Antibody is then added to detect the immobilized antigen. The quantity of antigen in the sample
can be inferred from a standard curve of reaction kinetics of the antibody and antigen.
Automation and parallelization of these conventional methods with microarray technology
have been extensively used to explore the expression of proteins on a large scale. For instance,
with an analytical protein microarray, the relative expression levels of thousands of proteins can
be determined in one experiment (Haab et al. 2001). Tissue microarrays have also made possible
the comparative expression study of one protein in multiple tissues in a single experiment
(Kononen et al. 1998). Miniaturization and parallelization of ELISA in microarray platform
results in the reverse phase microarrays, which allows the expression profiling of a single protein
in thousands of cell or tissue lysates (Paweletz et al. 2001; VanMeter et al. 2007; Espina et al.
2008). The exact amount of proteins expressed in these samples can be quantified by the use of
reference standards and serial dilution in reverse phase microarrays (Zhang et al. 2009).

Microarray Analysis
Microarray analysis, similar to recombinant DNA technology and polymerase chain
reaction (PCR), is a foundational technology with broad applications in areas including basic
research, safety assessment and disease diagnostics. The technology has been used in almost all
fields of biological and biomedical researches to analyze gene expression, genotyping, protein
function and metabolism.
Microarray technology started in the early nineties of the last century. At that time, it was
demonstrated that high-density arrays of peptides can be synthesized by photolithographic on
silicon synthesis (Fodor et al. 1991). This combinatorial synthetic technology was then applied to
6

oligonucleotides, generating the oligonucleotide arrays (Southern et al. 1992; Pease et al. 1994;
Southern and Maskos 1994; Lockhart et al. 1996). The development of oligonucleotide
microarrays was paralleled by that of cDNA microarrays (Schena et al. 1995; DeRisi et al. 1996;
Schena et al. 1996). These microarrays were manufactured by printing the PCR amplified
complementary DNA onto the array support.
The original microarray assay was to profile gene expressions at the transcriptional level.
This is usually done by comparing the messenger RNA (mRNA) abundance of all genes or
specific groups of genes in different samples, such as cancer versus normal, treatment vs. control;
or at different developmental times. Based on the experimental procedure, two methods have
been used to determine gene expression profiles with nucleic acid microarrays: single-channel
method and two-channel method (Fig 1.1). In a single-channel method, the mRNA from distinct
samples are extracted and labeled separately, but with same fluorescent tags. One microarray is
used for hybridization with each mRNA sample. The signals for each microarray are scanned
with same wavelength channel. The expression of each sample is then compared to one another
(Stears et al. 2003). In a two-channel method, the mRNAs from two distinct sample groups are
extracted and labeled with different fluorescent dyes (e.g. Cy3 and Cy5). The two labeled
samples are then mixed and delivered to the microarray containing thousands of probes for
competitive hybridization. The fluorescent signals of both channels are scanned at two different
wavelengths, and the ratio is used to infer the relative gene expression level for each gene of
interest between the two compared samples (Stears et al. 2003). The ability to make direct
comparisons between two samples on the same microarray slide is a unique and powerful feature
of the two-channel method. However, this method has some defaults when multiple samples are
of interest. To avoid this, various experimental designs including reference sample designs and
loop designs have been proposed (Churchill 2002; Vinciotti et al. 2005).
7

Figure 1.1 Expression analysis by nucleic acid microarray. a, Single-channel method uses a
single fluorescent label (green wavy lines) and two chips to generate expression profiles for two
cell samples. Genes with altered expression levels (green and red squares, respectively) are
identified by superimposing images obtained from different chips. b, Two-channel method uses
two different fluorescent labels (green and red wavy lines) and a single chip to generate
expression profiles for two different cell samples. Genes with altered expression levels (green
and red spots, respectively) are identified by superimposing images generated in different
channels on a single microarray. Genes expressed equally in the two samples appear as yellow
squares or spots in the two analyses. (Stears et al. 2003).
In addition to mRNA expression profiling, nucleic acid microarrays have diverse
applications in transcriptomic analysis. With slight differences in sample preparation and array
design, microarray systems with both the single-channel method and two-channel method have
been employed to interrogate transcription activities of non-coding RNAs (Kapranov et al. 2002;
Cawley et al. 2004; Kampa et al. 2004), to monitor differential miRNA expression profiles
(Sempere et al. 2004; Ramkissoon et al. 2006; Sood et al. 2006), to discover and characterize
alternatively spliced transcripts (Clark et al. 2002; Castle et al. 2003; Johnson et al. 2003), and to
identify target transcripts of RNA-binding proteins (Gerber et al. 2004).
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Nucleic acid microarrays have also found their ways in genomic analysis including the
complete resequencing of a genome relative to the reference sequence (Hacia 1999; Maitra et al.
2004; Wong et al. 2004), discovery of single nucleotide polymorphisms (SNPs) or single feature
polymorphisms (Chee et al. 1996; Winzeler et al. 1998; Borevitz et al. 2003; Turner et al. 2005),
SNP genotyping (Kallioniemi 2001; Fan et al. 2006), array comparative genome hybridization
(Pinkel et al. 1998; Pollack et al. 1999; Hughes et al. 2000; Iafrate et al. 2004; Maydan et al.
2007), identification of regulatory DNA sequences bound by transcriptional regulators (Ren et al.
2000; Iyer et al. 2001; Weinmann et al. 2002; Martone et al. 2003; Buck and Lieb 2004;
Euskirchen et al. 2004; Taverner et al. 2004), and interrogation of the DNA methylation profile
across the entire genome (Gitan et al. 2002; Lippman et al. 2005; Weber et al. 2005; Bibikova et
al. 2006; Schumacher et al. 2006).
Protein Microarrays
Protein microarrays have recently been in the limelight for their potential use in high
throughput studies of protein function (de Wildt et al. 2000; Emili and Cagney 2000; Kodadek
2001; MacBeath 2002; Bertone and Snyder 2005; Hall et al. 2007). Protein microarrays have
been utilized to study protein expression profiles (Knezevic et al. 2001; Sreekumar et al. 2001;
Schweitzer et al. 2002), protein post-translational modification (Pelech et al. 2008; Merbl and
Kirschner 2009) and protein-protein interactions (Uetz et al. 2000; Pawlak et al. 2002). These
microarrays have been applied to pharmacological and clinical areas including drug analysis
(Zhu et al. 2001; Huang et al. 2005) and diagnosis of diseases such as cancer, food allergies and
infection by pathogenic viruses and bacteria (Bacarese-Hamilton et al. 2002; Mezzasoma et al.
2002; Robinson et al. 2002; Woodbury et al. 2002).
The development of protein microarray technology has been propelled by the need to
explore the cellular system beyond the genomic and transcriptomic levels, and to characterize the
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collection of “working horses”, i.e. the proteome. Early studies of “multianalyte microspot
immunoassay” have demonstrated the feasibility of detecting biochemical activities of molecules
in miniaturized spot size with increased sensitivity (Ekins 1989; Ekins et al. 1990; Ekins and Chu
1991; Ekins and Chu 1992; Ekins 1998; Templin et al. 2002). These early studies laid the
foundation for the protein microarray technology. In addition, the great triumph in nucleic acid
microarrays has catalyzed the development of protein microarrays by providing platforms for
array manufacture and software programs for data process and analysis (Lueking et al. 1999; Ge
2000; Knezevic et al. 2001; MacBeath 2002).
Most of the current protein microarrays use the “capture” microarray platform in which an
array of probes is immobilized on a solid support such as glass slide or nylon membrane to
capture specific ligands from a protein mixture (Fig 1.2) (Kodadek 2001; MacBeath 2002;
Bertone and Snyder 2005). A number of molecules have been used for the manufacture of
protein microarrays, including synthetic peptides or aptamers (Roep et al. 2002; Collett et al.
2005), recombinant proteins (Ge 2000; MacBeath and Schreiber 2000; Zhu et al. 2001), and
antibodies (Lueking et al. 1999; Angenendt et al. 2002; Delehanty and Ligler 2002). Particularly,
on one type of arrays known as functional protein microarrays, the immobilized probes are
full-length functional proteins or protein domains (Wilson and Nock 2002; Jona and Snyder
2003; Predki 2004; Coleman et al. 2007). They are used to study a variety of protein interactions,
such as protein-protein, protein-DNA, protein-small molecule and enzyme-substrate interactions
(Predki 2004). Another type of the capture microarrays not containing the functional proteins are
known as analytical protein microarrays (Jona and Snyder 2003). These microarrays are
generally used to profile protein expression levels and measure binding affinity and specificity.
Among these, antibody microarrays are the most common platform (Bertone and Snyder 2005;
Wingren and Borrebaeck 2009).
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Figure 1.2 Schematic representation of capture protein microarray platform. a, an array of
ligands is immobilized on a membrane to captain proteins from a protein mixture such as cell
lysate; b, unbound proteins are washed away; c, bound proteins are detected with various
methods; d, detected signals are visualized.
Thousands of purified proteins are needed for the generation of high density protein
microarrays, especially functional protein microarrays. Recombinational cloning (Phizicky et al.
2003) and cell free expression (He and Taussig 2001) provide great tools for high throughput
expression. There are two major strategies for recombinational cloning: site-specific and random
recombinational cloning. Protein expression libraries created using random approaches from E.
coli (Lueking et al. 2003) or yeast (Zhu et al. 2001) have been described to construct protein
microarrays. The site-specific strategy makes use of the Gateway recombinational cloning
system (Walhout et al. 2000; Phizicky et al. 2003). Recently, a yeast proteome library of proteins
with C-terminal TAP tag was created using the Gateway system (Gelperin et al. 2005). Generally,
proteins expressed in a homologous system are more preferable for biochemical analyses using
microarray. Since the proteins are in their natural environment, they will undergo native
modifications and interact with their natural partners.
Independent of the system used for expression, proteins produced from recombinational
cloning have to be purified before they can be printed on the arrays. As an alternative approach,
11

cell free expression system utilizes in vitro transcription and translation. The direct production of
proteins from DNA on microarray support such as microscopic slides has been described (He
and Taussig 2001; Ramachandran et al. 2004). Using this system, interactions among human
proteins involved in DNA replication initiation have been mapped (Ramachandran et al. 2004).

a

b

Figure 1.3 Detection of bound proteins on microarray with labeling strategy. a, the bound
proteins are detected with pre-labeled antibodies. b, the bound proteins are labeled when
preparing the protein mixture and detected directly with scanning machine.
Two major strategies have been employed for the detection of bound target proteins on
capture protein microarrays: labeling and label-free strategy. Most capture protein microarrays
have employed some type of fluorescence labeling (MacBeath and Schreiber 2000; Zhu et al.
2001; Espejo et al. 2002; Chen et al. 2003; Lueking et al. 2003; Robinson et al. 2003), affinity
(Huang et al. 2004), chemiluminescent (Arenkov et al. 2000; Colca and Harrigan 2004) or
radioisotope tags (MacBeath and Schreiber 2000; Morozov et al. 2002). Among those,
fluorescent labels are generally preferred because they are safe and effective, and are compatible
with available laser scanners originally designated for nucleic acid microarrays. The labels may
be attached to a set of second antibodies (Knezevic et al. 2001; Sreekumar et al. 2001;
Schweitzer et al. 2002) if the ELISA-based “sandwich” detection is used (Fig 1.3a).
Alternatively, the label may be attached to the target itself (Haab et al. 2001) when preparing the
12

protein mixture, a legacy from nucleic acid microarrays (Fig 1.3b). Regardless of the types of
tags used, a chief problem with the labeling strategy is the possibility that the tags may interfere
with the binding interaction between the target and the probe. The label-free strategy may be
employed to overcome this problem. A number of label-free methods have been developed
recently, including surface plasmon resonance (SPR) (Gambari 2001), MS (Wright 2002), and
atomic force microscopy (Jones et al. 1998). SPR measures the local index of refraction, and is
the current leading technology for label-free detection (Ramachandran et al. 2005).
Dissociable Antibody Microarray (DAMA)
A different protein microarray platform has been developed (Wang 2004). This platform
can be used together with immunostaining, and form the DAMA staining technology. In DAMA
staining, targeted cells are grown or mounted on a coverslip, and then fixed and permeabilized
with standard protocols for immunostaining. In the next step, an array of primary antibodies
immobilized on a membrane is placed on top of the coverslip, with antibodies facing to cells.
Pressure is applied to maintain close contact of antibodies with cells. During incubation, the
antibodies dissociate from the array membrane and bind to their respective antigens in the cells
without significant lateral diffusion. In this way, hundreds of antibodies are delivered to the
targeted cells in a position-addressable manner. The bound antibodies are then detected either
with enzyme- or fluorophore-conjugated secondary antibodies (Fig 1.4). The expression and
SCL profiles of hundreds of proteins can thus be determined simultaneously. The key to this
technology is “dissociable”. Instead of capturing antigens on the array support as in capture
microarrays, DAMA staining delivers multiple antibodies to their antigens inside the cells. This
technology integrates the high-throughput of antibody microarrays with the power of
immunostaining, and provides a new approach in the global study of protein expression and SCL
in fixed cells or tissue samples.
13

Figure 1.4 Schematic representation of antibody array staining technology. 1, prepare
dissociable antibody microarray and adherent cells; 2, make contact between arrays and cells; 3,
remove array support; 4, detect bound antibodies. (Wang 2004)

Protein SCL Profiling
Intracellular compartmentalization is a key feature of eukaryotic cells to maintain the
integrity of cellular processes and pathways. The activities of individual proteins and protein
complexes are orchestrated by sequestration of related components into restricted spaces.
Therefore, knowledge of protein SCL provides useful information about a protein’s function,
activation state and interactions with other molecules. Ideally, SCL of protein reveals not only
where a protein is found, but also when it is found there and whether it changes localization.
Protein SCL can indicate what cellular pathways a certain protein functions in, and changes in
SCL may be the response to the cell signaling events caused by environmental and cellular
changes. In addition, co-localization of two proteins can support putative interactions proposed
from alternative methods.
Numerous cell biological studies have revealed that many membrane-bounded organelles
and structures such as cytoskeleton are centers for specific cellular functions. For instance,
mitochondria are the main sites of ATP production during aerobic metabolism, and the
localization of a protein to the mitochondrion is an indication that it is involved in cellular
14

respiration and electron transport chain. Similarly, localization of a protein to the centrosome
may suggest its role in chromosome separation during cell division. Nucleus, usually the largest
single organelle inside eukaryotic cells, has also been found to possess sub-compartmentalization
of functions (Dundr and Misteli 2001; Sutherland et al. 2001). For example, in the global SCL
analysis of budding yeast, 82 newly identified proteins were found to be localized in the
nucleolus, and are therefore predicted to be involved in ribosomal processing (Huh et al. 2003).
Many proteins change their SCLs in response to signals that change their state of activation.
Some proteins translocate from the cytosol to the nucleus. For instance, when a
receptor-regulated Smad (e.g. Smad3) is phosphorylated by activated TGF-beta receptors
following ligand binding, the cytosolic R-Smad proteins expose their nuclear localization signal
(NLS) and form complex with co-Smad (e.g. Smad4) and importin-beta. This large cytosolic
complex then translocates into the nucleus, where the Smad proteins regulate transcription by
association with transcription factors such as TFE3 (Moustakas and Heldin 2002; Hill 2009;
Wrighton et al. 2009). Upon recovery, Smad proteins are dephosphorylated and relocate to the
cytosol. Similarly, the Pho4 protein is involved in the cellular phosphate response of yeast, and
shuffling between the cytosol and nucleus. Under conditions of high phosphate, phosphorylation
of Pho4 by the cyclin-dependent kinase (CDK) complex Pho80–Pho85 leads to the rapid export
of Pho4 from the nucleus to the cytoplasm, where it is unable to activate transcription of
phosphate-starvation genes. When the cells are starved of phosphate, the CDK complex is
inhibited and unphosphorylated Pho4 enters the nucleus and induces expressions of several
phosphate starvation responding genes (Mouillon and Persson 2006).
Some proteins translocate from cytosol to the plasma membrane and membranes of internal
organelles. This protein translocation is important for many signaling events. For example, the
desensitization of G-protein coupled receptor (GPCR) signal involves the phosphorylation of the
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activated receptor by a GPCR kinase, which translocates from a cytosolic pool to the plasma
membrane. This is followed by recruitment of the multifunctional adapter protein β-arrestin to
the plasma membrane, which physically uncouples the G protein from the receptor (Luttrell and
Lefkowitz 2002; Lefkowitz and Shenoy 2005; Moore et al. 2007). Protein translocation from
cytosol to plasma membrane often involves lipid binding domains. An example is the activation
of the protein kinase C (PKC) isozymes. Increase of membrane diacylglycerol (DAG) levels and
usually calcium ion concentration in the case of cPKCs via activation of phospholipase C, results
in translocation of PKC-C2 domain from cytosol to plasma membrane. Subsequent binding of
PKC-C1 domain to DAG strengthens PKC-membrane association and exposes the binding sites
of the kinase domain, which triggers downstream events including activation of the MEK-ERK
and PI3K-Akt pathways (Newton 2003; Ali et al. 2009).
The SCL of a protein also has important implications about its interacting network.
Particularly, co-localization studies can serve as a way to filter the large numbers of
protein-protein interactions revealed from other methods such as yeast two hybrid (YTH) system
(Fields and Song 1989), or functional protein microarrays (Emili and Cagney 2000; Ge 2000).
For two proteins to interact, they have to reside in the same spaces at the time of interaction. Two
of the large-scale YTH studies used to screen all 6000 ORFs of yeast for binary interactions have
found 841 and 692 interactions respectively, but less than 20% of the identified interactions
overlap spatially within the cell (Uetz et al. 2000; Ito et al. 2001). This inconsistency indicates
the need of exclusion of false positive entries. Comparison of these data with localization data
can be one of the ways for this purpose. Indeed, in their proteome-scale analysis of protein SCL
in yeast, Kumar et al. sampled 105 protein interactions identified independently by both the
above groups, 87 were found to involve proteins sharing SCL pattern (Kumar et al. 2002). This
finding increased the confidence in those interactions.
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Methods for SCL Study
Many approaches have been employed to experimentally study protein SCLs. There are
mainly two strategies used. One of them is to separate various cellular components into different
fractions, and then to identify the protein composition of each. The other strategy is to visualize
protein SCL in situ with microscopy.
Traditionally, protein SCL studies using “separate and identify” strategy are made by use of
protein specific antibodies. In those early approaches, organelles were separated by
centrifugation, filtration or selective affinity isolation. To avoid the potential contamination
problem of organelle blending, analytical centrifugation such as density gradient centrifugation
was commonly used. After that, western blotting was performed to analyze protein distributions
throughout the gradient fractions. Since organelles were separated in the gradient, proteins that
reside in the same organelle were in the same fractions. Therefore, SCL patterns of unknown
proteins of interest could be assigned by comparing their gradient distributions to that of marker
proteins.
This strategy has been accommodated to analyze SCL in the proteome scale by combining
the fractionation steps with MS-based protein identification. Several studies have applied the
“fractionation-and-MS-based localization” strategy to characterize the proteome of single
organelles including mitochondria from the human heart tissue (Taylor et al. 2003) and budding
yeast (Sickmann et al. 2003), and human centrosome (Andersen et al. 2003). More recently,
proteomes of multiple organelles from Arabidopsis and mouse were mapped through the
combination of analytical centrifugation, MS-based protein identification and statistical data
analysis tools (Dunkley et al. 2004; Dunkley et al. 2006; Foster et al. 2006). The mammalian
organelle mapping by Foster et al. (2006) utilized protein correlation profiling for data analysis,
which estimates the goodness of fit of protein profiles relative to that of organelle markers. This
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study has assigned 1404 proteins to 10 subcellular locations in mouse liver (Foster et al. 2006).
Mapping of the Arabidopsis organelles by Dunkley et al. employed principle component analysis
to reduce the dimension of the total data set and the partial least square discriminant analysis to
assign protein SCL patterns with the marker proteins used as training set (Dunkley et al. 2006).
The visualization strategy of SCL study falls into two mainstreams: recombinant tagging
and immunostaining. The recombinant tagging approach is to visualize protein SCL in intact
cells by tagging the interested proteins either with a whole protein or a small epitope. The
tagging protein can be fluorescent protein like GFP and its spectral variants, and the SCL of the
proteins of interest can ready be observed under fluorescent microscopy. Small epitopes like the
Myc epitope may also tag the proteins of interest, and antibodies against the tag can be used to
visualize the protein SCL in cell. With the availability of genome sequence information, libraries
of cell strains with proteins fused to fluorescent proteins have been constructed for different
systems, such as utilizing oligonucleotide-directed homologous recombination for budding yeast
(Huh et al. 2003), mobile-elements-based chromosomal tagging for fruitfly (Morin et al. 2001)
and NIH 3T3 cells (Jarvik et al. 2002), and plasmid-based recombination cloning system for
Vero cells using human cDNAs (Simpson et al. 2000), fission yeast (Ding et al. 2000), and
tobacco (Escobar et al. 2003). These libraries have been employed for large-scale analysis of
protein SCLs in those organisms. Using directed topoisomerase I-mediated cloning strategies and
genome-wide mutagenesis, Kumar et al. have epitope-tagged 60% of the yeast proteome with
V5-epitope or HA-epitope and determined the SCL of 2744 proteins (Kumar et al. 2002).
Another widely accepted method for visualizing protein SCLs is immunostaining or IHC in
the case of tissues (Ramos-Vara 2005). Large scale study aiming to construct subcellular altas of
human proteome with immunostaining of monospecific polyclonal antibodies has been reported
(Barbe et al. 2008). In this pilot study, 3000 confocal images of 466 proteins in 3 human cell
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lines were generated. The same organization in Sweden has also examined the expression and
localization of proteins in nearly one hundred tissue and cell types, and maintained millions of
staining images generated from these studies (www.proteinatlas.org). IHC and tissue microarray
are the major techniques they used. However, the number of proteins can be explored in a single
classic immunostaining is limited due to antibody cross-talking and the spectrum overlay of
available labeling conjugates (Staines et al. 1988; Schieker et al. 2004). DAMA staining
technology combines the power of immunostaining with the parallel analytic capability of
protein microarrays (Wang 2004). The unique advantage of this technology is its ability to
determine the SCL profiles of hundreds of proteins from a single slide of the cultured cells or
tissue samples. We have further developed this technology by optimizing the experimental
protocol and establishing a data analyzing package (details in Chapter 3).
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CHAPTER TWO:
PROTEIN EXPRESSION PROFILING OF BREAST CANCER CELLS BY
DISSOCIABLE ANTIBODY MICROARRAY STAINING*

* This is a revision of the article originally published in Molecular & Cellular Proteomics
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Introduction
Protein microarrays have recently been attracting great attention for their potential use in
high throughput studies of protein function (de Wildt et al. 2000; Emili and Cagney 2000;
Kodadek 2001; MacBeath 2002; Bertone and Snyder 2005; Hall et al. 2007). The ultimate goal
of developing this technology is to construct ordered arrays of individual proteins for
biochemical study at the molecular level. A number of different sources of peptides and proteins
have been used for protein microarray manufacture, including synthetic peptides (Roep et al.
2002; Collett et al. 2005), recombinant proteins (Ge 2000; MacBeath and Schreiber 2000; Zhu et
al. 2001), and monoclonal and polyclonal antibodies (Lueking et al. 1999; Angenendt et al. 2002;
Delehanty and Ligler 2002). Microarrays have been utilized to study protein expression profiles
(Knezevic et al. 2001; Sreekumar et al. 2001; Schweitzer et al. 2002), protein-protein
interactions (Uetz et al. 2000; Pawlak et al. 2002), drug analysis (Zhu et al. 2001; Huang et al.
2005) and the diagnosis of diseases such as cancer, food allergies and infection by pathogenic
viruses and bacteria (Bacarese-Hamilton et al. 2002; Mezzasoma et al. 2002; Robinson et al.
2002; Woodbury et al. 2002). Most of the microarrays use the capture microarray platform
(Kodadek 2001; MacBeath 2002; Bertone and Snyder 2005). In a standard capture microarray
procedure, an array of proteins is immobilized on a membrane or a glass slide to capture protein
ligands from a protein mixture; the captured ligands are detected either with a different set of
labeled antibodies (Knezevic et al. 2001; Sreekumar et al. 2001; Schweitzer et al. 2002) or a
detectable tag attached to the ligands (Haab et al. 2001).
We have developed a different protein microarray platform, dissociable antibody
microarray (DAMA) staining (Wang 2004). This technology combines the power of
immunohistochemical staining and the parallel analysis of antibody microarrays. DAMA
staining provides a new approach in the global analysis of protein expression and subcellular
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localization (SCL). In DAMA staining, targeted cells are grown on a coverslip in a culture dish
or mounted on a coverslip and fixed and permeabilized with the standard protocol for traditional
immunostaining. In the next step, instead of adding a primary antibody, an array of antibodies
immobilized on a membrane is placed on top of the specimen. Pressure is applied to maintain
close contact between the antibody array and cells. During incubation, antibodies dissociate from
the array support and bind to their respective antigens in the cells without significant lateral
diffusion. In this way, hundreds of antibodies are delivered to the targeted cells or tissues in a
position dependant manner. The bound antibodies are then detected either with enzyme- or
fluorophore- conjugated secondary antibodies. The expression profiles of hundreds of proteins
can thus be determined simultaneously. Furthermore when stained with fluorophore-conjugated
secondary antibodies, SCL profiles of hundreds of proteins can be obtained from a single
staining by a fluorescence microscope equipped with a computer-controlled motorized stage.
Here we report the development of DAMA staining technology and its application in
identifying potential biomarkers for breast cancer. Breast cancer is the most common form of
cancer in women with ~ 210,000 new cases diagnosed annually in the United States alone
(Cooper 2001). This disease causes significant mortality, accounting for ~ 40,000 deaths in the
United States per year (Jemal et al. 2005) and many more fatalities worldwide. Earlier detection
and better treatment will improve prognosis and survival of the disease (Cooper 2001). Detection
of new molecular biomarkers will not only be very useful for breast cancer diagnosis but also
may identify novel and key targets for therapy. In this report, we compare the expression profiles
of 312 proteins among 10 different normal breast and breast cancer cell lines using DAMA
staining. We also developed a data analysis program to identify differentially expressed proteins
and validated the prediction by Western blotting analysis in the same set of cell lines.
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Table 2.1 Array-320 antibody list. Array-320 contains 312 antidodies in 16 rows (A to P) each with 20 columns (1 to 20). The
antigens of respective antibodies were shown in the corresponding positions as on the array, except that columns 11 to 20 were moved
to the lower part of the table.
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Experimental Procedures
Preparation of Antibody Microarray Array-320
Array-320 contains 312 antibodies in a 16 × 20 format. The antibodies were spotted on a
membrane by a robotic arrayer from Gesim (Dresden, Germany) using piezoelectrically driven
microdosage heads. This array has an overall size of 44 (width) × 42 mm (height) with 2 mm
between different antibody spots. Each spot contains 50 ng antibody and is about 500 μm in
diameter. The antibody list for Array-320 is shown in Table 2.1. Antibodies are selected from
Hypromatrix’s collection (Worcester, MA). All antibodies have been characterized and
demonstrated to bind their targets in various assays including western blotting and
immunostaining.
Cell Culture
Ten different breast cell lines, MCF10A, MCF12A, Hs578Bst, MCF7, T-47D, ZR-75-1,
MDA-MB-231, BT549, Hs578T and MDA-MB-435S, were purchased from American Type
Culture Collection (ATCC, Manassas, VA). MCF10A cells were maintained in Minimum
Essential Medium with additives 30 ng/ml human epidermal growth factor (hEGF) and 100
ng/ml chlora toxin. MCF12A cells were maintained in RPMI 1640 medium with additives 10
μg/ml insulin, 20 ng/ml hEGF, 100 ng/ml chlora toxin and 500 ng/ml hydrocortisone. Hs578Bst
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with additive 30 ng/ml
hEGF. ZR-75-1 cells were maintained in RPMI 1640 medium. MCF7, T-47D, and BT549 cells
were maintained in RPMI 1640 medium with 10 μg/ml insulin. Hs578T cells were cultured in
DMEM with 10 μg/ml insulin. These eight cell lines were cultured in a humidified incubator
(Fisher, Fair Lawn, NJ) at 37 ºC and 5% CO2. MDA-MB-231 and MDA-MB-435S cells were
cultured in Leibovitz’s L-15 medium at 37 ºC and 100% air. All media were supplemented with
10% fetal bovine serum, 10 U/ml penicillin, and 10 μg/ml streptomycin. Leibovitz’s L-15
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medium was purchased from ATCC. All other cell culture media and chemicals were purchased
from Invitrogen (previous GIBCO, Grand Island, NY).
DAMA Staining
Cells were grown on 10 cm cell culture dishes until 90-95% confluence and fixed with 3.7%
formaldehyde solution (Fisher) in Dulbecco's Phosphate-Buffered Saline (PBS, Sigma, St. Louis,
MO) at room temperature for 15 minutes. Fixed cells were permeabilized and blocked with a
blocking cocktail containing 0.5% Triton X-100 and 5% goat serum in PBS for 1 hour.
Array-320 was placed over the cells and was incubated at room temperature for 2 hours. After
washing with PBS for three times, alkaline phosphatase (AP) conjugated secondary antibodies
(both goat-anti-rabbit and goat-anti-mouse, Invitrogen) with a dilution of 1:2000 in PBS was
then applied to cells to detect the bound antibodies and incubated for 1 hour. After washing with
PBS for 3 times to eliminate unbound secondary antibodies, 1-stepTM NBT/BCIP (nitro blue
tetrazolium/5-bromo- 4-chloro-3-indolyl phosphate) substrate (Pierce, Rocklord, IL) was added
to cell to develop color. The color reaction was stopped by washing with PBS after 10 minutes of
incubation. Images of protein expression profiles were scanned by an HP Scanjet 4890 as 12-bit
grayscale images with a resolution of 2400 dots per inch (dpi).
Intensity Integration and Initial Data Analysis
The ScanAlyze program (http://rana.lbl.gov/EisenSoftware.htm) developed for DNA
microarray analysis was used for intensity integration of two DAMA staining images. The
scanned DAMA staining images were first compressed into 8-bit grayscale images with a
resolution of 600 dpi and color-inverted by Photoshop (Adobe System Inc.). The preprocessed
images were then combined into an RGB overlay image with one in red channel 1 and another in
green channel 2 with ScanAlyze program. A grid was created with a circular mask defining the
boundary for each spot. For the purpose of intensity integration, the location of the mask was
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refined for every spot. MRAT(i, j) values, the median ratio of intensity between channel 1 and
channel 2 within the mask, were determined and exported to an Excel file. The subsequent
analysis was done with the customized program DAMAPEP that was created with Microsoft
Visual Basic 6.0 IDE. Briefly MRAT(i, j) was converted to log2(MRAT(i, j)), normalized for all
312 proteins by subtracting the median log2(MRAT(i, j)) value, and scaled by dividing the root
mean square of all normalized log2(MRAT(i, j)) values. The median intensity of every spot and
their corresponding median and mean background values, CH1I, CH1B, and CH1AB for the
reference cell line R and CH2I, CH2B, and CH2AB for the sample cell line S, were also
exported for the analysis by the DAMAPEP program.
Western Blotting Analysis
Ten breast cell lines were grown on 10 mm cell culture dish in corresponding medium to
around 90-95% confluence. After washing with ice-cold PBS, cells were scraped off and
collected with centrifugation. Scraped cells were then lysed in lysis buffer (10 mM Tris pH 7.6,
50 mM NaCl, 5 mM EDTA, 30 mM Na4P2O7, 2 mM Na3VO4, 50 mM NaF, 1% Triton X-100, 1
mM DTT, 1 mM PMSF, 5 µg/ml Leupeptin, 5 µg/ml Aprotinin, 5 µg/ml Pepstatin A). The
extracts were sheared twice through a 20 gauge needle and centrifuged at 14,000 rpm for 15 min
at 4°C. The protein concentration of the cell lysates was quantified with Bradford Assay using
the Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA) and adjusted to the same values. Next,
the lysates were denatured in SDS sample buffer (30 mM Tris, 1% SDS, 5% glycerol, 25 mM
DTT, 0.005% bromphenol blue, pH 6.8) and heated at 95°C for 5 min. Equal amounts of the
denatured total protein were loaded onto 8-12% SDS-PAGE for separation. Proteins were then
transferred to nitrocellulose transfer membrane (Whatman, Inc.) with semi-dry transfer cell
(Bio-Rad). Membranes were blocked in a blocking solution (5% Non-fat milk, 20 mM Tris, 137
mM NaCl, 0.05% Tween-20, pH 7.6) for 1 hour at room temperature. Membranes were blotted
26

with primary antibodies in blocking solution with appropriate dilution at 4°C with gentle
agitation overnight. After washed with 1×TBS/T three times, membranes were incubated with
AP-conjugated secondary antibodies for 40 minutes at room temperature with gentle agitation.
After washing, the membranes were incubated with AP substrate and enhancer (Bio-Rad) for 5
minutes. Membranes were drained off and exposed to Kodak BioMax MR films for developing.
Gel Quantification and Statistical Analysis
For every protein, relative band densities of 10 cell lines were scanned and digitized by
UN-SCAN-IT software (Silk Scientific, Orem, UT). These values were normalized against the
highest value and averaged over all experiments. Relative expression levels of five proteins
between normal and cancer cells were analyzed by using the Student’s t test. For every protein,
expression levels in three normal cells and in seven cancer cells were analyzed by a two sample t
test assuming equal variances. The degree of freedom is 9 (n1=3, n2=7). The one-tailed p values
were used for statistical inference.

Results
Determining Protein Expression Profiles in Different Breast Cell Lines by DAMA Staining
DAMA staining is a high throughput technology that can simultaneously determine the
expression profiles and subcellular locations of hundreds of proteins (Wang 2004). The goal of
this work was to develop the DAMA staining technology for protein expression profiling and to
demonstrate its application in identifying potential biomarkers for breast cancer. The technology
includes the following steps: determination of protein expression profiles by DAMA staining,
data extraction by the ScanAlyze program, data analysis and prediction by the DAMAPEP
program, and evaluation by Western blot analysis.
For this purpose, protein expression profiles of 10 different cell lines from human mammary
glands were obtained from DAMA staining (Fig. 2.1). The 10 breast cell lines include three
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Figure 2.1 Summary of DAMA staining images in 10 different breast cell lines. The images were obtained by using the
312-antibody microarray, Array-320. The distance between the spots is 2 mm, and the dimensions of the images within four corner
spots is 38 mm in width and 30 mm in height. The cell line names are labeled either above or below the corresponding images. The
spot positions are labeled from A to P for rows and from 1 to 20 for columns. Experiments were repeated at least twice and one set of
results is shown here. The Pearson’s correlation coefficients (Rr) of two replicated images for all 10 cell lines are included.
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normal lines (MCF12A, MCF10A, and Hs578Bst), three estrogen receptor-positive carcinomas
(T-47D, MCF7, and ZR-75-1), and four estrogen receptor-negative carcinomas (MDA-MB-231,
BT549, Hs578T, and MDA-MB-435S). The cells were grown on a 10 cm cell culture dish to
90-95% confluence, fixed and permeabilized by a standard protocol. Array-320 was then used to
deliver an array of 312 primary antibodies to those fixed cells. Bound antibodies were detected
by using AP-conjugated secondary antibodies. The resulting array of grey dots were imaged and
subjected to intensity integration and data analysis to generate expression profiles for the 312
proteins. The experiments were repeated at least twice for each cell line. The representative
images and the Pearson’s correlation coefficients (Rr) of the replicated images for all ten-breast
cell lines are summarized in Fig. 2.1. Most cell lines have reproducible DAMA staining images
with the Pearson’s correlation coefficients higher than 0.5.
Intensity Integration of the DAMA Staining Images by ScanAlyze
The images obtained from DAMA staining were analyzed using standard methods for
intensity integration, normalization, and scaling. Among the 10 breast cell lines, one normal cell
line, MCF10A, was used as a common reference for intensity integration. The other nine cell
lines were used as sample cell lines. The DAMA staining images of the nine cell lines were
individually compared with the image of MCF10A by using ScanAlyze, an intensity integration
program for DNA microarrays. Protein expression profiles between different samples were
quantitatively compared by ScanAlyze with one image (e.g. the reference cell line R) as the
channel 1 data and the other image (e.g. the sample cell line S) as the channel 2 data. MRAT(i,
j), the median intensity ratio between channel 1 and channel 2 at the spot of the ith row and jth
column (spot(i, j)), was exported. The logarithm of the MRATs of each pair was normalized and
scaled by using a procedure similar to that used for data analysis of DNA microarrays.

29

Initial Data Analysis for the DAMA Staining Images with Program DAMAPEP
A program, DAMAPEP (DAMA protein expression profiling), was developed to retrieve,
normalize, and scale the data from the exported ScanAlyze files. The method for this data
analysis is shown in Fig. 2.2. As the protein expression profiles for each cell line were
determined at least twice, there are two independent DAMA staining images for each spot: two
for the sample cell line (S1 and S2) and two for the reference cell line (R1 and R2). Therefore,
four different sets of MRAT values, MRAT(1, 1), MRAT(1, 2), MRAT(2, 1) and MRAT(2, 2),
corresponding to the intensity ratios of S1 to R1, S1 to R2, S2 to R1, and S2 to R2, respectively,
were obtained for every spot(i, j) (Fig 2.2a). The logarithms of those MRAT values were
normalized and scaled. The average of those scaled log2(MRAT(i, j)) values, defined as SigS(i, j),
represents the intensity change between the sample cell line (S) and the reference cell line (R) for
the protein at spot(i, j) (Fig. 2.2c, Equation 1).
To determine the experimental errors for the sample and reference spots, the MRAT value
between the two sample cell line images, defined as MRATS, was calculated from ScanAlyze by
including those two images as channel 1 and channel 2. Using a similar approach, MRATR was
also calculated by using the two images of the reference cell line. As the theoretical MRATS(i, j)
and MRATR(i, j) values for every spot(i, j) should be 1.0, the absolute average of the scaled
log2(MRATS(i, j)) and scaled log2(MRATR(i, j)) values, defined as the background BKS(i, j),
represents the experimental error for the protein at spot(i, j) (Fig. 2.2c. Equation 2).
Comparison of the Protein Expression Profiles with Program DAMAPEP
After calculating signal (SigS(i, j)) and background (BKS(i, j)) values for all spots, the
program DAMAPEP identifies those proteins differentially expressed between normal and
cancer cell lines. For this purpose, three different criteria were utilized to identify those candidate
proteins from the DAMA staining images (Fig. 2.2b).
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Figure 2.2 Schematic of intensity integration and data analysis by DAMAPEP. a, intensity
integration and initial data processing for the duplicated DAMA staining images. S1 and S2
represent two independent DAMA staining images for the sample cell line S, and R1 and R2
represent two images for the reference cell line R (such as MCF10A). For every sample cell line,
each image was compared with one image of the reference cell line by the ScanAlyze program.
Thus, four corresponding MRAT values were determined for each protein on the array. The
average of the scaled log2(MRAT) values, SigS, represents the intensity change between the
sample cell line S and the reference cell line R (Equation 1 in c). Similarly, ScanAlyze was used
to calculate MRATS and MRATR, the MRAT values between the two images of sample cell line
S and between the two images of reference cell line R. The sum of the absolute value of their
scaled values, BKS, represents the experimental error (Equation 2 in c). b, flow chart for data
analysis. To compare the expression profile of 312 proteins in 10 breast cell lines, one of the
normal cell lines, MCF10A, was chosen to be a common reference. Expression profiles of the
other nine cell lines were compared with that of the common reference using the schemes in a.
The resulting SigS for normal and cancer cell lines were used to obtain the average intensity of
the two normal cell lines and seven cancer cells over the reference cell line, namely SigNor and
SigCan, respectively (Equations 3 and 4 in c). The ratio of the difference between SigNor and
SigCan over SigNor was calculated to represent the average intensity change between cancer cells
and normal cells relative to that of the normal cells. To qualify as differentially expressed
proteins, the absolute ratio values of the proteins have to be larger than 2 and the channel
intensities have to be greater than either the mean or median channel backgrounds. Additionally,
at least four of the cancer cell lines must have SigS be greater than BKS. c, formulas used for data
analysis.
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First, a decision was made according to the average intensity change of the protein at spot(i,
j) between all cancer cells and all normal cells. SigCan(i, j), defined as the average SigS(i, j) for all
seven cancer cells was calculated for every spot(i, j) (Fig. 2.2, b and c, Equation 3). This value
represents the average intensity change of the protein at spot(i, j) in all cancer cell lines relative
to the reference cell line MCF10A. Similarly SigNor(i, j), the average SigS(i, j) for two normal
cells, was also calculated for every spot(i, j) (Fig. 2.2c, Equation 4). SigNor(i, j) corresponds to
the average intensity change of the protein at spot(i, j) in other normal cell lines relative to the
intensity in the reference cell MCF10A. The Ratio(i, j) calculated (Fig. 2.2c, Equation 5) thus
represents the average intensity change of the protein at spot(i, j) between cancer cells and
normal cells relative to that of the normal cells (Fig. 2.2b). The higher the absolute value of
Ratio(i, j), the larger the intensity difference. Therefore, DAMAPEP can predict a list of proteins
with different expression levels between normal and cancer cells based on the selected cut-off
value of Ratio(i, j).
When 2.0 was used as a cut-off value of Ratio(i, j), 54 proteins were predicted as the
differentially expressed proteins between normal and cancer cells. However, 22 of the 54
proteins had lower spot intensity in at least one of the 10 cell lines. The contribution of those
weak intensity spots to the corresponding value of Ratio(i, j) could be enlarged. To test the
possibility, the expression levels of eight proteins, randomly selected from the 22 proteins, were
compared among 10 cell lines by western blotting analysis. All eight proteins showed low or
undetectable expression levels (data not shown). Therefore, to decrease false positives caused by
lowered spot intensity, DAMAPEP automatically compares the intensity of each spot with their
background from the ScanAlyze exported files (CH1I versus CH1B and CH1AB; CH2I versus
CH2B and CH2AB). The spots with intensities lower than their corresponding backgrounds in
any one of the cell lines were excluded from the final prediction list (Fig. 2.2b).
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The third criteria, Sigcan(i, j) (the averaged SigS(i, j) values for all seven cancer cell lines),
could easily be biased by large numbers in one or two cell lines. To eliminate this bias, the
SigS(i, j) value was compared with the corresponding background BKS(i, j) for all seven cancer
cell lines. Only those proteins at spot (i, j) having more than four cell lines with higher SigS(i, j)
value than the corresponding background value BKS(i, j) were included in the final prediction list
(Fig. 2.2b).
Identifying the Differentially Expressed Proteins between Normal and Cancer Cell Lines
by DAMAPEP
As discussed above, the expression profiles of 312 proteins obtained by the DAMA staining
for 10 breast cell lines were repeated at least twice and were analyzed by the programs
ScanAlyze and DAMAPEP. When using a minimum cutoff value of 2.0 for the absolute value of
Ratio(i, j), 10 of 312 proteins (leukemia inhibitory factor receptor alpha, Tyk2, Rb p130, SRF,
c-Kit, Rb p107, RAIDD, Mos proto-oncogene, IκB-β and IL-2Rβ were predicted by DAMAPEP
to have different expression levels in cancer cells versus normal cells (Fig. 2.3a). The first seven
proteins were predicted to have higher expression levels in cancer cells, and the latter three were
predicted to have lower expression levels. Their corresponding dots in the DAMA images for all
10 cell lines demonstrated the consistency between the DAMAPEP prediction and the original
DAMA staining data especially for those confirmed proteins (Fig. 2.3b and Fig. 2.4). When the
cut-off value for Ratio(i, j) was decreased from 2.0 to 1.5 (representing a 50% intensity change
between normal and cancer cells) six extra proteins were added into the prediction list. Among
them, ErbB3, c-Raf and Rad52 were predicted to have higher expression in cancer cells and Fas
(TNFRSF6)-associated death domain protein, FLICE inhibitory protein (short/long), and IL-1R
were predicted to have lower expression. However, none of these six proteins was confirmed to
have the predicted difference by western blotting analysis (data not shown). Therefore, 2.0 was
used as the cut-off value for Ratio(i, j) in the DAMAPEP prediction.
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Figure 2.3 Proteins predicted from DAMAPEP to have different expression levels between normal and cancer cells. a, the
DAMAPEP predicted proteins were shown with their name, position in the DAMA staining images, and their corresponding Ratio
values ranked from high at the left to low at the right. b, Summary of the corresponding dots in the DAMA staining images shown in
Fig 2.1 for the seven proteins predicted by DAMAPEP with increased expression levels in carcinoma-originated cell lines. LIFR,
leukemia inhibitory factor receptor alpha.
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Figure 2.4 Boxplot of correlation coefficients for the ten predicted proteins in all the ten
tested breast cell lines. The correlation coefficients were calculated by ScanAlyze for the
replicated images of each cell line. The overall ranges were shown by whiskers. The interquatile
ranges (IQRs) were shown by boxes with the median values in asterisks.
Expression Levels of the Predicted Proteins by Western Blotting
To evaluate the prediction accuracy of DAMAPEP, expression levels of the above 10
proteins predicted with the 2.0 cutoff value were examined by Western blotting. Among the
seven proteins predicted with increased expression in cancer cells, five proteins, RAIDD, Rb
p107, Rb p130, SRF, and Tyk2, were confirmed to have higher expression (Fig. 2.5a). For the
other five proteins predicted with DAMAPEP, increased expression level of leukemia inhibitory
receptor factor alpha was only detected in some cancer cell lines. For c-kit and IL-2Rβ, no bands
were observed in Western blots in any cell lines probably due to extremely low expression
levels. The expression levels of Mos proto-oncogene and IκB-β were similar in both normal and
cancer cell lines (data not shown). The expression of RAIDD was almost undetectable in the
three normal cell lines. The expression of Rb p107, SRF, and Tyk2 in normal cells was between
15 and 40% of their expression in cancer cells. The expression of Rb p130 in normal cells was
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about 20% of its expression in cancer cells (Fig. 2.5b). Mean values of the normalized expression
of RAIDD, Rb p107, Rb p130, SRF, and Tyk2 in three normal cell lines are 5 versus 61% (p =
0.0032), 26 versus 81% (p = 0.0041), 18 versus 69% (p = 0.0055), 25 versus 73% (p = 0.0033)
and 30% (p = 0.0012), respectively (Fig. 2.5c). Those data confirm that RAIDD, Rb p107, Rb
p130, SRF, and Tyk2 are indeed overexpressed in the tested cancer cells.

Discussion
DAMA staining is a novel platform for protein microarray analysis that can determine both
expression and SCL profiles of hundreds of proteins in targeted cell and tissue samples. We
developed this unique technology for protein expression profiling and developed a program,
DAMAPEP, for intensity integration and data analysis. We demonstrated the application of this
technology for potential biomarker identification by comparing the expression profiles of 312
proteins among 10 different breast cell lines. Seven proteins with higher expression levels and
three proteins with lower expression in cancer cells were predicted from the DAMAPEP
program. Among them, five proteins (RAIDD, Rb p107, Rb p130, SRF, and Tyk2) were
confirmed to have higher expression in seven tested cancer cell lines relative to three normal cell
lines. A similar approach could be widely applied to other biomedical research such as
biomarker identification and signal transduction studies. Compared with other captured antibody
microarrays, DAMA staining can determine the protein expression profiles for more than
hundreds of proteins in a more convenient way.
The observed higher expression levels of two proteins in breast cancer cells are consistent
with published reports. The increased expression of Rb2/p130 gene was observed in majority of
breast cancers (Milde-Langosch et al. 2001). Up-regulated and highly active SRF was observed
in squamous epithelial tumor cells (Psichari et al. 2002). However, we are not aware of any
studies addressing the expression changes of RAIDD, Rb p107, and Tyk2 in breast cancer.
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Among the seven proteins predicted with higher expression level in breast cancer cells, five
were confirmed by Western blot analysis. On the other hand, none of the three proteins predicted
to have lower expression levels were confirmed by Western blotting. These errors could be
caused by the quality of the DAMA staining images. For example, images of MCF7, ZR-75-1
and BT549 have a higher density in the lower part of the array (Fig. 2.1). This uneven intensity
distribution could be caused by uneven pressure applied during primary antibody staining. In
addition, the lower part of the array corresponds to the center of the culture dish, which could
have higher cell density and therefore might result in the observed uneven distribution
Two cell lines with lower Pearson’s correlation coefficients, Hs578Bst and ZR-75-1, could
also affect the prediction accuracy. The overlap coefficients for these two cell lines, a modified
Pearson’s correlation coefficient where the average grey value of each image was not subtracted
from the original grey value of each pixel, were also lower. Those data suggested that
superimposition of those images was not perfect possibly due to their lower spot intensities. The
situation was improved by increasing the spot diameters for intensity integration by ScanAlyze.
Therefore, the prediction accuracy could be improved by better DAMA staining images after
further optimizing the experimental conditions. Another possible reason for the inaccurate
prediction of decreased expression levels is systematic bias in data analysis especially in the
normalization procedure. As there are only 312 proteins in the dataset, and most proteins are
highly regulated, the assumption that those 312 proteins should have the same expression levels
among different samples could generate systematic bias during data normalization. This
systematic bias could be decreased by including additional antibodies on the array. In addition,
deploying multiple replicate spots for each antibody on the array could also increase data
accuracy, decreasing experimental error and increasing prediction accuracy.
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Figure 2.5 Validation of DAMAPEP predicted results. a, western blotting confirms that five proteins have higher expression levels
in cancer cells. Total cell extracts of the ten breast cell lines were prepared as described in “Experimental Procedures”. Equal amounts
of total lysates, as shown for actin, were loaded for western blotting analysis. Proteins are labeled at the left of the gel and tested cell
lines are labeled at the top. N1, N2 and N3 represent three normal cell lines, ER+1, ER+2 and ER+3 represent three estrogen
receptor-positive carcinoma cell lines, and ER-1, ER-2, ER-3 and ER-4 represent four estrogen receptor-negative carcinoma cell lines.
b, relative expression of five proteins in ten breast cell lines. Western blot analysis for every protein was repeated at least three times.
The average values for every protein in different cell lines are shown here with error bars corresponding to their S.D. c, box plot of the
relative expression of five proteins in three normal cell lines and seven cancer cell lines, using the data shown in b. The ranges of
expression levels in the group of normal cell lines versus the group of cancer cell lines are shown side by side for every protein. The
interquartile ranges are shown by boxes with the median values in filled triangles. N, normal; C, cancer; HQ, higher quartile; LQ,
lower quartile.
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The AP-based detection with its narrow detection range of signal intensity could be another
reason for the inaccuracy of the method. The intensity difference between the strongest spot and
the weakest spot of the staining images as determined by the protein expression level and
antibody affinity could be hundreds of thousands-fold. The weak spot may obscure the difference.
For example, both ER-positive and ER-negative cell lines were utilized. However, the DAMA
staining for antibody against ER at spot F5 in all cell lines showed weak signal. This could be
improved by using a fluorescent conjugated secondary antibody and a fluorescence scanner. We
tried several commercial microarray scanners but failed to obtain adequate signals. A more
sensitive scanner may be needed for our purpose. In addition, the homogeneity of cell samples
and the percentage of cell confluence could also affect the accuracy of protein expression
profiling. For this reason, cells were grown to 90-95% confluence for the consistency. Under
current experimental conditions, 10 of 320 proteins were identified by the DAMA staining as
differentially expressed proteins, and their expression patterns are consistent with those obtained
by Western blot analysis, confirming the accuracy and broad application of the DAMA staining
technology.

Summary
Dissociable Antibody MicroArray (DAMA) staining is a technology that combines protein
microarrays with traditional immunostaining techniques. It can simultaneously determine the
expression and subcellular location of hundreds of proteins in cultured cells and tissue samples.
We developed this technology and demonstrated its application in identifying potential
biomarkers for breast cancer. We compared the expression profiles of 312 proteins among three
normal breast cell lines and seven breast cancer cell lines and identified 10 differentially
expressed proteins by the data analysis program DAMAPEP (DAMA protein expression
profiling). Among those proteins, RAIDD, Rb p107, Rb p130, SRF and Tyk2 were confirmed by
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Western blot and statistical analysis to have higher expression levels in breast cancer cells than
in normal breast cells. These proteins could be potential biomarkers for the diagnosis of breast
cancer.
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CHAPTER THREE:
PROTEIN SUBCELLULAR LOCALIZATION PROFILING OF BREAST
CANCER CELLS BY DISSOCIABLE ANTIBODY MICROARRAY
STAINING
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Introduction
Proteomics is an active and highly diverse field that uses different techniques to
characterize and quantify the content of the proteomes and to understand their structures and
interaction network, their posttranslational modifications and their relation to biological function
(Falk et al. 2007). Among the techniques used in proteomics, protein microarrays have recently
been attracting great attention for their potential use in high-throughput studies of protein
function (de Wildt et al. 2000; Emili and Cagney 2000; Kodadek 2001; MacBeath 2002; Bertone
and Snyder 2005; Hall et al. 2007), and microarrays have been utilized for studying protein
expression profiles (Knezevic et al. 2001; Sreekumar et al. 2001; Schweitzer et al. 2002),
protein-protein interactions (Uetz et al. 2000; Pawlak et al. 2002), for drug analysis (Zhu et al.
2001; Huang et al. 2005) and for the diagnosis of diseases such as cancer, food allergies and
infection by pathogenic viruses and bacteria (Bacarese-Hamilton et al. 2002; Mezzasoma et al.
2002; Robinson et al. 2002; Woodbury et al. 2002). Most of those microarrays use the capture
microarray platform (Kodadek 2001; MacBeath 2002; Bertone and Snyder 2005) that determines
the protein expression and modification profiles by using the lysate of the targeted samples.
Of equal importance as profiling protein expression and post-translational modification
patterns, is profiling the localization of proteins in different subcellular compartments.
Knowledge of protein localization has important implication of its activation state, its interaction
network and its biological function. For instance, the nuclear localization of NF-κB is consistent
with its activation through dissociation from I-κB proteins, which mask the nuclear localization
signals of NF-κB in their cytosolic complex (Baeuerle and Henkel 1994; Siebenlist et al. 1994).
One approach for studying protein localization is to separate the proteins of individual organelles
by separating the organelles into different cellular fractions. The components of each fraction can
then be identified on a large scale with mass spectrometry (Dreger 2003; Tan and Arias 2006).
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An alternative approach is to visualize protein SCL in intact cells by fusing the interested
proteins with fluorescent proteins, such as utilizing oligonucleotide-directed homologous
recombination for budding yeast (Huh et al. 2003), mobile-elements-based chromosomal tagging
for fruitfly (Morin et al. 2001) and NIH 3T3 cells (Jarvik et al. 2002), and plasmid-based
recombination cloning system for Vero cells using human cDNAs (Simpson et al. 2000), fission
yeast (Ding et al. 2000), and tobacco (Escobar et al. 2003). These techniques have been
employed for large-scale analysis of protein SCLs in those organisms. Another widely accepted
and versatile method for visualizing protein subcelluar localizations is immunostaining. However,
the number of proteins that can be explored in one stain is limited, due to antibody cross-talking
and the spectrum overlap of available labeling conjugates (Staines et al. 1988; Schieker et al.
2004).
We have developed a novel technology called Dissociable Antibody MicroArray (DAMA)
staining technique (Wang 2004) that combines the power of immunohistochemical staining with
the parallel analytic capability of protein microarrays. This technology provides a new approach
in the global analysis of both protein expression and SCLs in fixed cells. We have developed this
technology and demonstrated its application in identifying potential biomarkers for breast cancer
by profiling the expression of 312 proteins (Chapter 2). The unique advantage of this technology
is its ability to determine the SCL profiles of hundreds of proteins from a single slide of the
tested samples. Here we developed and optimized the technology for protein SCL profiling of
hundreds of proteins in different breast cell lines, and developed a computer program for
management and comparison of thousands of molecular images for those proteins in different
cell line samples. We also identified and validated one protein with altered SCLs between
normal and cancer breast cell lines.
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Table 3.1. Antibody list of 360 proteins as arranged in ChipView. Four antibody arrays were
employed in this study, namely Arrays I-IV. Protein names in this table are arranged in the same
order as their antibodies were printed on the arrays. Reference spots (Histone H1) are marked red
(6 on each array). The four antibody arrays are organized in such a way that the final list and
ChipViews possess rectangular shape. Briefly, Array I and II are on A1-H12 with a background
color of yellow and A13-H24 with a bright green background color respectively, and Array IV
are on the lower right (J13-O24, with a background color of rose). For display purpose, Array III
(with a background color of sky blue) are segmented into two parts, with the second row of
images (B1-B12) being taken out and placed between Array II and IV on the right (I13-I24). The
rest rows of Array III follow their layout on the array and positioned in the low left (I1-O12).
Therefore, to find the proteins which the antibodies at the position of B01 on each array are
against, one should locate B01 (I), B13 (II), I13 (III) and K13 (IV).
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Experimental Procedures
Preparation of Antibody Microarrays
Four different antibody microarrays (Antibody Staining Array I – IV) were used for the
experiments. Arrays I – III each contains 96 antibody spots in a 8 x 12 format, and Array IV
contains 72 antibody in a 6 x 12 format. Trial membrane contains 12 antibody spots in a 3 x 4
format. The antibodies were spotted by a robotic piezoelectric non-contact microarrayer on a 2 x
2 cm membrane. The antibodies in Arrays I – III have an overall size of 11 (width) x 7 mm
(height), with 1 mm between different antibody spots, and the antibodies in Array IV have an
overall size of 11 x 5 mm. The antibodies in trial membrane have an overall size of 3 x 2 mm.
Each spot contains 50 ng antibodies and is ~200 μm in diameter. The antibody lists for Staining
Array I-IV are shown in Table 3.1. Antibodies are selected from Hypromatrix’s collection. All
antibodies have been characterized and demonstrated to bind their targets in various assays such
as western blotting and immunostaining.
Cell Culture
Nine breast cell lines, MCF10A, Hs578Bst, MCF7, T-47D, ZR-75-1, MDA-MB-231,
BT549, Hs578T and MDA-MB-435S, were purchased from American Type Culture Collection
(ATCC, Manassas, VA). MCF10A cells were maintained in Minimum Essential Medium with
additives 30 ng/ml human epidermal growth factor (hEGF) and 100 ng/ml chlora toxin.
Hs578Bst were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with additive 30
ng/ml hEGF. MCF7, T-47D, and BT549 cells were maintained in RPMI 1640 medium with 10
μg/ml insulin. ZR-75-1 cells were maintained in RPMI 1640 medium. Hs578T cells were
cultured in DMEM with 10 μg/ml insulin. These seven cell lines were cultured in a humidified
incubator (Fisher, Fair Lawn, NJ) at 37 ºC and 5% CO2. MDA-MB-231 and MDA-MB-435S
cells were cultured in Leibovitz’s L-15 medium at 37 ºC and 100% air. All media were
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supplemented with 10% fetal bovine serum, 10 U/ml penicillin, and 10 μg/ml streptomycin.
Leibovitz’s L-15 medium was purchased from ATCC. All other cell culture media and chemicals
were purchased from Invitrogen (previous GIBCO, Grand Island, NY). Cells were passed
routinely on 10 cm culture dishes, and were grown on 2 x 2 cm coverslips and harvested at
90-95% confluence for DAMA staining and individual classic immunostaining.
DAMA Staining
Cells were fixed with 3.7% formaldehyde solution (Fisher) in Dulbecco's Phosphate
Buffered Saline (PBS, Sigma, St. Louis, MO) at room temperature for 15 minutes. Fixed cells
were permeabilized and blocked with blocking cocktail containing 0.5% Triton X-100 and 10%
goat serum in PBS for 45 minutes. Antibody microarrays were placed over the cells and were
incubated at room temperature. A weight of 0.2 kg, the optimal weight as identified from
optimization experiments, was placed on top of the staining apparatus for 2 hours. After washing
3 times with PBS to eliminate unbounded antibodies, bound antibodies were detected by
Alex488-conjugated secondary antibodies (both goat-anti-rabbit and goat-anti-mouse, Invitrogen)
diluted 1:800 in PBS for 30 minutes. After rinsing with PBS, cells were stained with DAPI for 5
minutes. After washing 3 times with PBS to eliminate the unbound secondary antibodies and
DAPI dyes, the coverslips were mounted on a microscope slide for fluorescent microscopy.
Automatic Image-Taken System
The molecular images of 72 or 96 proteins were obtained from a single cell culture
coverslip by using a Leica DM RXA2 Deconvolution system. The system includes an upright
microscope (Leica DM RXA2, Leica Microsystem), a 12-bit CCD camera (SensiCamQE, The
Cooke Corporation), a motorized stage with the X-Y movement, and a controlling program with
the multi-well capture package (SlideBookTM, Intelligent Imaging Innovation, Inc). As
anti-Histone H1 antibody was spotted at the four corners of the array, those spots with strong and
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characteristic nucleus staining were identified manually under the microscope. The positions
corresponding to the up-left (UL), up-right (UR) and low-right (LR) spots of staining array on
each slide were registered to SlideBook, which could determine the orientation of the studied
slide and use the information and the spatial parameters of the array to calculate the positions of
all the spots with antibody staining. SlideBook then automatically moved the motorized stage to
each and every spot and took molecular images of the corresponding proteins. The captured
images were transferred via local area network to the image data server for further analysis.
Individual Classic Immunostaining
Cells were fixed with 3.7% formaldehyde solution in PBS at room temperature for 15
minutes. Fixed cells were permeabilized and blocked with blocking cocktail containing 0.5%
Triton X-100 and 10% goat serum in PBS for 45 minutes. Primary antibodies dissolved in
blocking cocktail with a dilution of 1:500 were delivered to the cells and were incubated at room
temperature for 2 hours. After washing 3 times with PBS to eliminate unbounded antibodies,
bound antibodies were detected by Alex488-conjugated secondary antibodies diluted 1:800 in
PBS for 30 minutes. After rinsing with PBS, cells were stained with DAPI for 5 minutes. After
washing 3 times with PBS to eliminate the unbound secondary antibodies and DAPI dyes, the
coverslips were mounted on a microscope slide. The standard capture package of Leica DM
RXA2 Deconvolution system was used to observe and capture images.
Western Blotting Analysis
The nine breast cell lines were grown on 10 cm cell culture dishes in corresponding medium
to around 90-95% confluence. After washing with ice-cold PBS, cells were scraped off and
collected by centrifugation. Scraped cells were then lysed in lysis buffer (10 mM Tris pH 7.6, 50
mM NaCl, 5 mM EDTA, 30 mM Na4P2O7, 2 mM Na3VO4, 50 mM NaF, 1% Triton X-100, 1
mM DTT, 1 mM PMSF, 5 µg/ml Leupeptin, 5 µg/ml Aprotinin, 5 µg/ml Pepstatin A). The
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extracts were sheared twice through a 20 gauge needle and centrifuged at 14,000 rpm for 15 min
at 4°C. The protein concentration of the cell lysates was quantified with Bradford Assay using
the Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA). Next, the lysates were denatured in SDS
sample buffer (30 mM Tris, 1% SDS, 5% glycerol, 25 mM DTT, 0.005% bromphenol blue, pH
6.8) and heated at 95°C for 5 min. Equal amounts of the denatured total protein were loaded onto
10% SDS-PAGE for separation. Proteins were then transferred to nitrocellulose transfer
membrane (Whatman, Inc.) with semi-dry transfer cell (Bio-Rad). Membranes were blocked in a
blocking solution (5% Non-fat milk, 20 mM Tris, 137 mM NaCl, 0.05% Tween-20, pH 7.6) for 1
hour at room temperature. Membranes were blotted with primary antibodies in blocking solution
with appropriate dilution at 4°C with gentle agitation overnight. After washed with 1×TBS/T
three times, membranes were incubated with AP-conjugated secondary antibodies for 1 hour at
room temperature with gentle agitation. After washing, the membranes were incubated with AP
substrate and enhancer (Bio-Rad) for 5 minutes. Membranes were drained off and exposed to
Kodak BioMax MR films for development.

Results
We have previously demonstrated that the molecular images of proteins obtained using the
DAMA staining have similar quality to those obtained by classic immunostaining (Wang 2004).
The goal of this work was to develop the technique for protein SCL profiling and to demonstrate
its application in identifying proteins with different SCLs between normal and cancer breast cells.
The experimental procedure includes the following steps: optimization of the experimental
conditions, determination of the protein SCL profiles by DAMA staining, database construction
and data analysis by CHIPVIEW program, identification of proteins with altered SCLs in normal
and cancer breast cells, and evaluation of the identified proteins by classic immunostaining.
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Figure 3.1 Optimization of DAMA staining conditions for protein SCL profiling. a, effect of
different pressure applied during array incubation on DAMA staining images. Higher pressure
caused cells be peeled off during membrane removing, and low pressure resulted in lower signal
level and greater spot diameter. b, effect of different cell confluence on the DAMA staining
images. DAMA staining image of 50% cell confluence cannot be obtained with the automatic
image-taken system and hence not shown here. Cell confluence of 90% or more resulted in
good-quality images. c, effect of fixation methods on the DAMA staining images. All three
methods tested resulted in acceptable image quality.
Optimization of DAMA Staining Conditions for Protein SCL Profiling
To obtain high quality of images with the DAMA staining technology, the experimental
conditions, such as the pressure applied for antibody delivery, the optimal confluence of sample
cell density and the fixation methods, were optimized with MDA-MB-231 cell, a breast cancer
cell line (Fig 3.1). At first, the optimal pressure for the DAMA staining was explored. For this
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purpose, the cells grown to around 90% confluence were stained with trial membrane under
different weights, range from 0 to 1.0 kg. Lower pressure resulted in lower signal levels with less
delivered antibodies and greater spot diameter due to lateral diffusion because of not enough
tight contact. Higher pressure resulted in the cell peeled off during membrane removing. The
optimal images were obtained from MDM-MB-231 cells using 0.2 kg weight on top of the array
membrane (Fig 3.1a). Next, images of MDA-MB-231 cells grown to different confluence,
ranging from 50% to 100% confluence, and stained with trial membrane under the optimal
pressure (0.2 kg weight) were compared. The result suggested that cells grown to 90% or higher
confluence yield optimal images (Fig 3.1b). Finally, the images for cells fixed by three different
fixation protocols widely used for immunostaining, formaldehyde, methanol and the mixture of
methanol and acetone were compared. All three different protocols gave same quality of images
(Fig 3.1c). Therefore, the optimal condition for MDA-MB-231 cells was identified as growing
cells to about 90% confluence, fixing cells with 3.7% formaldehyde at room temperature for 15
minutes, and applying a 0.2 kg weight above the array membrane during primary antibody
staining. This condition was compatible with other cell lines and resulted in high quality images.
Determination of SCL Profiles of 360 Proteins in Nine Breast Cell Lines by DAMA
Staining
After identifying the optimal conditions, protein SCL profiles of nine different cell lines
from human mammary glands were obtained from DAMA staining. The nine breast cell lines,
MCF10A, Hs578Bst, T-47D, MCF7, ZR-75-1, MDA-MB-231, BT549, Hs578T and
MDA-MB-435S, were grown on standard coverslips to 90-95% confluence, and fixed and
permeabilized by a standard formaldehyde protocol. 360 antibodies were delivered to the fixed
cells through four different antibody Arrays (AntibodyArray I, II, III and IV). Bound antibodies
were then detected using fluorophore-conjugated secondary antibodies. Images of 360 proteins,
each repeated five times, were captured in the green channel with the DAPI staining images in
51

the blue channel, by using the automatic image-taken system (microscope equipped with a
computer-controlled motorized stage). A total amount of about 16200 molecular images were
obtained and stored to a data server for database construction and analysis.
Database Management and Image Analysis by Chipview
CHIPVIEW, a database-based graphical user interface (GUI) program, was developed to manage
and analyze the large amount of molecular images obtained above (Fig 3.2). An image database
was established and expanded by importing original images of 360 proteins in nine cell lines
through the program. The database holds images and related sample information such as array
type, sample name, experimental conditions, and SCL patterns, in interrelated tables. This
relational database design facilitates the search and presentation of images by their biological or
experimental information. The program can assign a custom-defined SCL code for each protein
and can compare the molecular images of every protein in all samples as discussed below. The
program can also select a representative molecular image for all the 360 proteins in one cell line,
and stitched them together as a Chipview picture, which represents the SCL profile of these
proteins in this cell line. The chipview pictures of 360 proteins, in Hs578Bst cell line, a normal
breast cell line and T-47D cell line, a breast cancer cell line, are shown in Fig 3.3. The chipviews
for the rest of the cell lines are shown in Fig 3.4. Totally, 3240 representative molecular images
were incorporated in the 9 chipviews.
Initial Validation of Protein SCL Profiles Obtained by DAMA Staining
The protein SCL in different breast cell lines was assigned by visually assessing each
molecular image with the Chipview program. Based on whether or not the green channel signal
of the captured image overlapped with its blue channel signal of DAPI staining, the SCL of the
studied protein in each cell was defined as in nuclei, in cytoplasm or in both places, and was
assigned as N, C, and B, respectively. The SCL of the specific protein in a molecular image was
52

Figure 3.2 ChipView Program for Image Analysis. a, design schema of ChipView. The main
goals of ChipView program are to store molecular images obtained from DAMA staining into a
database for analysis, and to present the SCL profiles. These are achieved by two functional
modules: the database management module and the visualization and analysis module. The
database management module allows users to import and maintain the image database. The
visualization and analysis module presents the images in different manners to facilitate visual
inspection of the images. For example, images of the same protein in different cell lines can be
aligned in a window for comparison, or images of all proteins in one cell line can be stitched into
a chipview. b, flowchart of ChipView program to manage and analyze molecular images
obtained through DAMA staining. The images are first imported into a database created by the
program (1). Then, the intensity and contrast of images are adjusted for better display and those
images with poor quality are removed from the database (2). After that, the molecular images of
each protein in different cell lines are compared and assigned a SCL code in the compare view
(3). Finally, a chipview with all the representative images for all proteins in the tested cell line
were constructed to represent the SCL profile of these proteins in the cell (4). The image
adjustment can also be triggered in compare view or chipview (5, 6).
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Figure 3.3. Chipview picture of the representative molecular images of 360 proteins in one
benign breast cell line (Hs578Bst) (a) and in one breast cancer cell line (T-47D) (b) obtained
by the DAMA staining technique. The molecular images of 360 proteins obtained from DAMA
staining were first imported into a database. Their representative images were selected to
construct the picture by using the ChipView program (Fig 3.2) and arranged in the same layout
as antibody list shown in Table 3.1. Each image represents the image of the corresponding
protein in the tested sample. For those proteins whose molecular images at 63x magnification
were not good, black images were used.
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Figure 3.4 Chipviews of 360 proteins in the other 7 breast cell lines not shown in Figure 3.3.
a, MCF7; b, ZR-75-1; c, MDA-MB-231; d, BT549; e, Hs578T; f, MDA-MB-435S; g, MCF10A.
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assigned with the most dominant SCL pattern of that protein in the image. For the proteins with
poor quality images due to low protein expression, out of focus or without cells in the captured
images or proteins with uncertain images (no single dominant SCL pattern in the image), a code
“U” was assigned.
In order to examine the accuracy of the SCL profiles assigned from the DAMA staining
images, the SCL profiles of 96 proteins, stained with AntibodyArray I, were obtained and
compared between two independent experiments for T47D and MCF10A cell line samples,
respectively. Molecular images of 96 proteins were captured using the automatic image-taken
system with a 63x objective lens. Their SCLs in the two independent image datasets were
assigned and compared. In T47D cell line sample, 73 proteins have the identical SCL
assignments between the two image sets and 20 proteins were assigned as U from one of the
image sets. Only 3 proteins were assigned differently between the two image sets. In MCF10A
cell line sample, 64 proteins have the identical SCL assignments between the two independent
image sets and 23 proteins were assigned as U from one of the image datasets. Only 9 proteins
were assigned differently between the two independent sets. The discrepancy and large number
of U in at least one image set were resulted from the systematic focus deviation and
heterogeneity of cell status in one of two experiments. Even though, the above results suggested
that reproducible SCL profiles could be obtained from the DAMA staining experiments.
Compare SCL Profiles of Image Datasets Obtained with Different Objective Lens
In order to evaluate the accuracy of the SCL profiles obtained from the DAMA staining, all
the images for 9 different cell lines were captured independently by using the 20x objective lens
or by using the 63x objective lens. The SCLs in each and every image of the 20x dataset and in
that of the 63x dataset were assigned by visual inspection using Chipview program. The assigned
codes from two independent dataset were compared (Fig 3.6a). The consistency of SCL
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assignments from two image datasets ranges from 91% to 100% in 9 different cell lines, with the
average of 95% consistency. For the SCL assignment of all 3240 proteins in 9 cell lines, about
70% were assigned the identical code without any uncertainty from two datasets (codes other
than “U”), 25% were assigned “U” in at least one dataset, due to low quality images in either
image set. This result suggested that the SCL profiles assigned from the 63x image dataset were
consistent with those assigned from the 20x image dataset.
SCL Profiles of 360 Proteins in 9 Different Breast Cell Lines
The SCL profiles of 360 proteins in 9 different breast cell lines were summarized in Fig 3.5.
Each colored bar represented the SCL of the specific protein in the specific cell line. Red, green
and yellow colored bars represent that the specific protein was localized in the nuclei (N),
cytoplasm (C) and both places (B), respectively, as assigned from their DAMA staining images.
The final SCL assignments were determined by incorporating the assignments from both the 20x
image dataset and the 63x image dataset (Fig 3.5). Among these assignments, an average of 13%
proteins were assigned as “N”, 61% proteins were assigned as “C”, and 16% proteins were
assigned as “B” in seven cancer cell lines. The average percentage of proteins assigned to a code
“N”, “C” and “B” in two normal cell lines is 30%, 10% and 48% respectively (Fig 3.6b). Out of
the 360 proteins, one protein, Cyclin B1, was identified to have different SCL assignments
between the normal and cancer cell lines (Fig 3.6c). This protein distributed evenly within most
cells of the two normal breast cell lines, and localized mainly in the cytoplasm of the majority of
the cells of the seven breast cancer cell lines.
Validation of the Assigned Protein SCLs by Individual Immunostaining
To evaluate the accuracy of assigned SCL profiles from the DAMA staining images, the
images of 30 proteins, randomly picked from the data sets and evenly distributed in the four
arrays, were obtained by individual traditional immunostaining and were compared with their
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Figure 3.5 SCL profiles of 360 proteins in the nine tested benign and carcinoma derived
breast cell lines. The SCL profiles are presented with a customer-defined color codes. Red,
represents that the corresponding protein is localized in the nuclei in the specific cell line; green,
represents the corresponding protein is localized in cytoplasm; yellow, represents the
corresponding protein is localized both in nuclei and in cytoplasm; and black represents the SCL
of the corresponding protein in uncertain. The final SCL assignments were determined by
incorporating the assignments from both the 20x image dataset and the 63x image dataset. If the
assignments of images from two magnification dataset are same, the same code is used; if the
two are different and both have “non-U” code (N, C, B), then a “U” is given; if images from any
of the two sets has been assigned “U”, then the code from the other set will be used in the final
assignment. Each column represents the SCL codes of the proteins in the same cell line, and each
row represents the SCL codes of the same protein in different cell line samples. Those proteins
identified with different SCLs between the benign and cancer cell lines were marked by asterisks
at the end of the row. The cell lines corresponding to the labels on the figure are: N1: MCF10A,
N2: Hs578Bst, T1: T-47D, T2: MCF7, T3: ZR-75-1, T4: MDA-MB-231, T5: BT549, T6:
Hs578T, T7: MDA-MB-435S.
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Figure 3.6 Summary of SCL profiles of 360 proteins in nine breast cell lines, as assigned
from the images obtained with the DAMA staining technology. a, analysis of the
reproducibility of the assigned SCL codes. Case 1 (X|X) represents those proteins which have
same certain assignments (not “U”) in both 20x and 63x images; case 2 (U|X) represents the
proteins which have an uncertain assignment (“U”) in either 20x images or 63x images; case 3
(X|Y) represents the proteins which have certain assignments in both the 20x and 63x images,
but are different from one another. b, summary of the statistics of the assigned SCL distribution
in nine breast cell lines. c, the molecular images of Cyclin B1 obtained from the DAMA staining
in the nine breast cell lines possessing different SCL codes in benign and carcinoma derived cell
lines. The cell lines corresponding to the labels on the figure are: N1: MCF10A, N2: Hs578Bst,
T1: T-47D, T2: MCF7, T3: ZR-75-1, T4: MDA-MB-231, T5: BT549, T6: Hs578T, T7:
MDA-MB-435S.
images obtained from the DAMA staining technique (Table 3.2). Among the 30 proteins, the
SCL assignments of four proteins were confirmed in all eight examined cell lines by individual
immunostain; the SCL assignments of ten proteins were confirmed in seven out of eight
examined cell line and those of fifteen proteins were confirmed in six out of eight examined cell
lines. Only one protein whose SCL assignment was confirmed in five out of eight examined cell
lines. The inconsistency is mainly assigned as “C” from one image and assigned as “B” in the
other images, due to the poor quality of DAMA staining images. Therefore, among the SCL
codes assigned for 240 molecular images obtained from the DAMA staining, 197 have been
confirmed by individual immunostaining.
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Table 3.2 Validation of assigned SCL codes from the DAMA staining images by individual
immunostain for 30 randomly selected proteins. The corresponding assigned SCL codes were
shown with one letter, when confirmed by individual immunostaining, or two letters separated
by a forward slash with the code from DAMA images on the left and the code from individual
staining on the right. Those with different non-“U” SCL codes were marked green, and
considered as inconsistency between the two methods.

Cyclin B1 Was Confirmed to Have Different SCLs Between Normal and Cancer Breast
Cell Lines
From the comparison of SCL profiles, Cyclin B1 was identified to have different subcellular
distribution between normal and cancer cell lines. The observed SCL difference of Cyclin B1 in
9 different cells were examined and confirmed by individual immunostaining (Fig 3.7a). Cyclin
B1 shows a cytoplasm pattern in the seven tested cancer cell lines but distributes nearly even in
both nuclei and cytoplasm in the two normal cell lines. In addition, the intensity of the
immunostained Cyclin B1 images in normal cell lines was much lower than that in the cancer
cell lines, which suggested the possible lower expression of Cyclin B1 in normal cell lines than
in cancer cell lines. Indeed, the expression level of Cyclin B1 was confirmed to be much lower in
normal cell lines than in cancer cell lines by the western blotting analysis (Fig 3.7b). The
expression of Cyclin B1 was nearly undetectable in the two normal cell lines. The expression of
Cyclin B1 varied in the seven cancer cell lines but each was higher than that in normal cell lines.
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Figure 3.7 Cyclin B1 was confirmed to have altered SCL and expression in benign and
carcinoma derived breast cell lines. a, individual immunostain confirmed Cyclin B1 to have
altered SCL in benign and carcinoma derived breast cell lines as determined by DAMA staining
(fig 3c). b, expression of Cyclin B1 in the 9 cell lines determined by western blot. The cell lines
corresponding to the labels on the figure are: N1: MCF10A, N2: Hs578Bst, T1: T-47D, T2:
MCF7, T3: ZR-75-1, T4: MDA-MB-231, T5: BT549, T6: Hs578T, T7: MDA-MB-435S.

Discussion
Dissociable antibody microarray (DAMA) staining is a novel protein microarray platform
that can be used to study both protein expression and SCL profiles in a high throughput fashion.
In this report, the molecular images of 360 proteins in 9 breast cell lines were obtained by using
the DAMA staining technology and were analyzed with a program for database management and
analysis, namely Chipview. The SCL profiles of these proteins in the nine breast cell lines were
determined and reported in a single color code profile. The SCL patterns of those proteins
between normal and cancer breast cell lines were examined. One protein, cyclin B1, was
identified as distributed evenly throughout the whole cell with lower expression in normal cell
lines, while localized mainly in the cytoplasm with higher expression in cancer cell lines.
DAMA staining is in essence the combination of microarray technology with large numbers
of classic immunostainings. To our knowledge, this is the first technique that can determine the
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SCLs of hundreds of proteins from a single experimental sample. The microarray with 400
antibodies has been developed and the microarray with a thousand antibodies is also achievable.
We have demonstrated the application of the technique on identifying unique SCL among
different cell line samples. The technique could also be a powerful technique in studying the
SCL profiles and trafficking of hundreds or thousands of proteins following signal stimulation.
In this work, we determined the SCL of proteins by visual inspection of their molecular
images against DAPI staining one by one. This manual annotation of images is labor intensive
and tends to involve annotator’s subjectivity, especially when certain patterns are expected with
previous knowledge. Therefore, an attractive expansion of this work could be to develop new
algorithms for automatic assignment of protein localization patterns cell by cell by utilizing the
colocalization information of the studied protein with the organelle markers. A pilot study
(Chapter 4) utilizing the colocalization information of the proteins studied and the nuclear
marker DAPI in 2-D images has shown the feasibility of such strategy. However, more technical
developments are needed to identify and segment cells from their surrounding. Other strategy for
this purpose can be to utilize the pattern recognition approach as shown in multiple studies
(Boland et al. 1998; Roques and Murphy 2002; Murphy 2005). Still there is a need to have
images with single cell only and to setup a standard of each pattern for training the machine.

Summary
We have developed Dissociable Antibody MicroArray (DAMA) staining technology that
provides a new approach in the global analysis of protein SCL in fixed cells. We developed and
optimized this technology for protein SCL profiling, and generated ChipView, a program for
management and analysis of molecular image database and have utilized the technique to
identify proteins with unique SCL in breast cancer cell lines. We compared the SCL profiles of
325 proteins among nine breast cell lines, and identified one protein, Cyclin B1, with different
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SCLs between normal and cancer cell lines. With individual immunostaining, Cyclin B1 was
confirmed to localize in the cytoplasm of seven tested cancer cells and in both cytoplasm and
nuclei of two normal cells and to have higher expression levels in seven cancer cell lines.
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CHAPTER FOUR:
OTHER DEVELOPMENTS AND APPLICATIONS OF DISSOCIABLE
ANTIBODY MICROARRAY STAINING
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Introduction
Dissociable antibody microarray (DAMA) staining has proven useful in the differential
analysis of protein expression and SCL in multiple breast cell lines on a large scale for potential
biomarker discovery (Chapters 2 and 3). In addition to the profiling studies in cell lines, DAMA
staining can also be extended to interrogate protein expression and SCL in tissue samples. The
number of proteins per array on the DAMAs in the SCL profiling study was about 100, and four
arrays were used. It is necessary to enlarge the scale of antibody arrays so that more proteins can
be investigated in a single experiment and the experimental variation can be reduced. This
chapter summarizes expansions of DAMA staining technique including application in tissue
samples, increase of array scale, and development of automatic SCL assignment program.
Immunohistochemical (IHC) investigations are useful for characterizing and classifying
carcinomas in addition to the histological and cytological observations. Various kinds of
antibodies are available for characterization and classification of tumors (Yaziji and Gown 2001;
Yaziji et al. 2006; Jablonska and Jesionek-Kupnicka 2008), and new antibodies are being
developed (Dowsett and Dunbier 2008; Schroder 2009). Generally, multiple antibodies are used
to diagnose poorly-differentiated malignant tumors. The immunoreactivities of multiple antigens
in the same case may also be of interest. Conventional IHC examination of multiple antibodies in
the same tissue specimen requires individual staining of each antibody in different slides of the
tissue sections, making it necessary to change slides repeatedly. This can be cumbersome,
time-consuming, and costly even with automatic immunostaining systems. Therefore, a method
that allows IHC study of a tissue with a panel of antibodies in a single slide will be greatly
advantageous. DAMA staining technique can be used to survey hundreds of proteins in tissue
samples. We have demonstrated the application of DAMA staining in tissue samples by
comparing the expression and distribution of 96 proteins in two breast tissue samples.
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Prostate carcinoma is the most common form of cancer in men and the second leading cause
of death estimated to account for over 28,000 deaths per year in the United States (Jemal et al.
2008). Diagnosis of prostate carcinomas can be difficult in needle biopsies or in minimal residual
cancer of radical prostatectomies (DiGiuseppe et al. 1997). The architectural or cytological clues
to a diagnosis of carcinoma may not always be seen in small biopsy samples. In addition,
carcinoma glands may closely resemble nonmalignant glands. Therefore, it would be very useful
to have a molecular marker for prostate cancer diagnosis. We have recently constructed a DAMA
with 400 antibodies on a single microarray, and used it to explore the potential biomarkers for
prostate cancer diagnosis.
One way to determine the SCL of a protein is to interrogate its colocalization with organelle
markers in the molecular image. Biologically, colocalization refers to the presence of two or
more different molecules in the same compartment of the cell. Since the development of digital
multicolor microscopy imaging, colocalization of two proteins was estimated by superimposing
the molecular images of them and then judging through the overlap of signals visually by
researchers. Although naked-eye judgment can tell whether two molecules colocalize, it lacks the
power to quantitatively determine the degree of colocalization even when it seems obvious.
Moreover, the visual inspection of molecular images to determine SCL is difficult to automate
and is thus labor intensive. The large volume of images produced by using DAMA staining calls
for a more efficient strategy to derive SCL patterns by analyzing the colocalization information
of proteins interested and the localization probes. We have developed a program for this purpose.

Experimental Procedures
Preparation of Antibody Microarrays
Antibody Staining Array-400 was used for SCL profiling of prostate cancer cell lines.
Antibody Staining Array-I was used for the profiling experiments of tissue samples. Array-400
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and Array-I contain 400 and 96 antibody spots respectively. The antibodies were spotted by a
robotic piezoelectric non-contact microarrayer. Each spot contains 50 ng antibodies within an
area of ~200 μm in diameter, and is separated from the neighboring spots by 1 mm. Antibody
spots of Array-400 are in 16 x 25 format, occupying an area of 16 mm x 25 mm on a membrane
with the size of 2 cm x 4 cm. Spots of Array-I are in 8 x 12 format on a 2 x 2 cm membrane. The
antibody list for Array-400 and Array-I are shown in Table 4.1 and Table 3.1 respectively.
Antibodies are selected from Hypromatrix’s collection. All antibodies have been characterized
and demonstrated to bind their targets in various assays such as western blot and immunostain.
Cell Preparation
Six prostate cells, PWR-1E, PZ-HPV-7, RWPE1, VCaP, DU145 and LNCaP clone FGC,
were purchased from American Type Culture Collection. PWR-1E, PZ-HPV-7, RWPE1 cells
were maintained in Keratinocyte-Serum Free medium supplemented 5 ng/ml human epidermal
growth factor and 50 μg/ml bovine pituitary extract. VCaP cells were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS), 4 mM
L-glutamine, 1.5 g/L sodium bicarbonate, and 4.5 g/L glucose. DU145 cells were maintained in
Minimum Essential Medium supplemented with 10% FBS, 2 mM L-glutamine, 1.5 g/L sodium
bicarbonate, 0.1 mM non-essential amino acids, and 1 mM sodium pyruvate. LNCaP clone FGC
cells were maintained in RPMI 1640 medium 2 mM L-glutamine, 1.5 g/L sodium bicarbonate,
4.5 g/L glucose, 10 mM HEPES, and 1 mM sodium pyruvate. All media contain 10 U/ml
penicillin, and 10 μg/ml streptomycin. The six cell lines are cultured in a humidified incubator at
37 ºC and 5% carbon dioxide. Cells were passed routinely in 10 cm culture dishes and were
grown on 2 x 2 cm coverslips to 90-95% confluence for staining purposes. All media and
chemicals were purchased from Invitrogen. Harvested cells were fixed with 3.7% formaldehyde
solution at room temperature for 15 minutes for DAMA and individual staining.
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Table 4.1 Array-400 antibody list.
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Table 4.1 continued
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Tissue Sample Preparation
Two tissues sections (A80:40314-4 and B73:15536-3) were obtained from two different
breast cancer patients and generously provided by Dr. Zhong Jiang at UMASS Medical School.
The tissue sample preparation protocol for staining was also obtained from Dr. Jiang’s lab. The
formalin-fixed, paraffin-embedded tissue blocks were cut into 5-μm sections, transferred to glass
slides. The paraffin was cleared with xylene twice in fresh dishes each for 10 minutes. The slides
were then moved to a fresh dish of xylene:alcohol 1:1 for 5 minutes, followed by decreasing
alcohol solution for 2 minutes each (100% and 95% twice, 80% and 50% once). The slides were
moved to ddH2O for 10 minutes. Next, the de-paraffined slides were incubated with 10 mM
citrate buffer, pH6.0 at 95 ºC for 10 minutes for antigen retrieval before stain.
DAMA Staining
Preprocessed cells or tissue samples were permeabilized and blocked with a blocking
cocktail containing 0.5% Triton X-100 and 10% goat serum in PBS for 45 minutes (1 hour for
tissue samples). Antibody microarrays were placed over the samples and incubated at room
temperature. A weight of 0.2 kg was added on top of the staining apparatus for 2 hours. After
washing 3 times with PBS to eliminate the unbound antibodies, bound antibodies were then
detected by Alex488-conjugated secondary antibodies (both goat-anti-rabbit and goat-anti-mouse)
diluted 1:800 in PBS for 30 minutes. After a brief rinse with PBS, cells were stained with DAPI
for 5 minutes. After washing 3 times with PBS to eliminate the unbound secondary antibodies
and DAPI dyes, the coverslips were mounted on a microscope slide for fluorescent microscopy.
Individual Classic Immunostaining
Classic immunostaining of cells with individual antibodies were performed with the
standard protocol. The samples were prepared with same protocol as for DAMA staining.
Primary antibodies diluted 1:500 in PBS were delivered to the cells and incubated at room
temperature for 2 hours. After washing 3 times with PBS to eliminate the unbound antibodies,
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bound antibodies were detected by Alex488-conjugated secondary antibodies diluted 1:800 in
PBS for 30 minutes. After rinsing with PBS, cells were stained with DAPI for 5 minutes or
wheat-germ agglutinin conjugated with Alex555 (WGA) for 5 minutes. After washing 3 times
with PBS to eliminate the unbound secondary antibodies and dyes, the coverslips were mounted
on a microscope slide for fluorescent microscopy.
Automatic Image-Taken System
The molecular images determined by DAMA staining were obtained using a Leica DM
RXA2 Deconvolution system. The system includes an upright microscope (Leica DM RXA2,
Leica Microsystem), a 12-bit CCD camera (SensiCamQE, The Cooke Corporation), a motorized
stage with the X-Y movement, and a controlling program with the multi-well capture package
(SlideBookTM, Intelligent Imaging Innovation, Inc). The four corner spots with strong and
characteristic anti-Histone H1 nuclear staining were identified manually under the microscope.
The positions of all the spots on an array were calculated by SlideBook, which then
automatically moved the motorized stage to each spot and took molecular images of the
corresponding proteins.
Image Acquisition of Individual Staining
The molecular images determined by classic individual staining of tissue samples were
obtained by using the ordinary capture mode of Leica DM RXA2 Deconvolution system. The
individually stained molecular images of GRK2 were captured with a Leica TCS SP2 spectral
confocal microscope equipped with a 63X/1.4NA oil immersion objective and He/Ne lasers. The
laser lines used for excitation were 488nm (for Alex488) and 543nm (for WGA Alex555).
Images were acquired in sequential steps (i.e. one for each dye) to minimize the spectral bleed
through. The detector gain and offset were adjusted for each sample to use the full dynamic
range of the detector and highest signal to noise ratios possible.
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Figure 4.1 DAMA staining of tissue samples identified three proteins with altered
expression and distribution in the two tissue samples. a, ChipView of 96 proteins from
Antibody Staining Array I in tissue A80:40314-3. b, detailed comparison of expression patterns
of 3 proteins (HSP70, p53 and Stat1) in the two tissue samples used. c, Individual immunostain
confirmed altered expression patterns of the three proteins in the two tissue samples.

Results
Application of DAMA Staining on Tissue Samples Identified 3 Proteins with Different
Expression Patterns in Breast Tissues
In addition to monitoring protein expression and SCL in cultured cell samples, DAMA
staining technology is also applicable to tissue samples. To demonstrate this potential, we have
compared the expression and distribution of 96 proteins in two breast tissue samples from
different patients by using DAMA staining. Antibody Staining Array-I was used to stain two
different tissue sections. Chipview of low resolution images of one tissue section are shown in
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Fig 4.1a. The expressions of 3 proteins were found to be different in these two tissue samples
(Fig 4.1b), which were confirmed with conventional immunostaining using individual antibodies
(Fig 4.1c). However, the biological relevance and significance of this result was not studied.
SCL Profiling by DAMA Staining with Array-400
The DAMAs used for SCL study described in Chapter 3 contain up to 96 antibodies per
array. Recently, we have constructed Array-400 with 400 antibodies on a single microarray, and
used it in exploring the SCL patterns of the arrayed antibodies in five normal and cancer prostate
cell lines. In the preliminary studies, the molecular images of those 400 antibodies in the five
prostate cell lines (PWR-1E, PZ-HPV7, LNCaP clone FGC, VCaP, and DU145) were determined
using DAMA staining technique and captured with a 20x magnification lens. Visual comparison
of these images using ChipView has identified five proteins to have altered SCLs among normal
and cancer prostate cell lines (Fig 4.2).
Confirmation of Altered SCLs of GRK2 in Normal and Cancer Prostate Cell Lines
So far, one protein has been confirmed with altered SCLs between normal and cancer
prostate cell lines using individual classic immunostaining of the five cell lines and another
normal cell line (RWPE1) we recently obtained. This protein, GRK2, shows a ubiquitous
cytosolic distribution in the three normal cell lines (PWR-1E, PZ-HPV7, RWPE1) and one
cancer cell line (LNCaP clone FGC). In the other two cancer cell lines (DU145, VCaP), it
appears to locate in specific regions under the plasma membrane (Fig 4.3). More cell lines and
tissues may be included to validate the possibility of using this protein as potential biomarker for
prostate cancer diagnosis. It will also be interesting to investigate the mechanism for the altered
SCL in the two prostate cancer cell lines.
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Figure 4.2 Chipviews of 400 proteins in normal and cancer prostate cell lines obtained by
DAMA staining. The molecular images of 400 proteins obtained from DAMA staining were first
imported into a database. Their representative images were selected to construct the picture by
using the ChipView program (Figure 3.2) and arranged in the same layout as on the antibody
array. Each image represents the image of the corresponding protein in the tested cell lines. For
those proteins whose SCLs were identified as different between normal and cancer cell lines,
their molecular images are pseudo-colored red. Molecular images of other proteins keep the
same color as they were captured under microscope. a, PWR-1E . b, PZ-HPV7. c, LNCaP. d,
VCaP. e, DU145.
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Figure 4.3 Classic individual immunostaining confirms the altered SCL patterns of GRK2
in normal and cancer prostate cell lines. The 6 prostate cell lines were co-stained with
antibody against GRK2 (green) and wheat-germ agglutinin (red) that marks membrane systems.
Images were taken using confocal microscopy with 40x lens. a, PWR-1E . b, PZ-HPV7. c,
RWPE-1. d, LNCaP. e, VCaP. f, DU145. Selected regions in the images of cancer prostate cell
lines are shown in separate channel in the subsets below the images to show the relative
localization of GRK2 to the plasma membranes.
DAMASCL for Automatic SCL Assignment of Molecular Images
A program, DAMASCL (abbreviation of DAMA staining SubCellular Localizer), was
development to determine the SCL of target proteins by quantitatively estimating the
colocalization levels of the proteins of interest and a localization probe. This program first reads
the multi-channel tiff image files to extract the intensity values separately for each channel. After
the background correction, the various coefficients of three intensity-based pixel groups are
calculated for each image. The program determines the SCLs of target proteins by specific
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criteria based on those coefficients (Fig 4.4). The corresponding coefficients and assigned code
for three sample images are shown in Fig 4.5. The SCL patterns of these typical images were
correctly assigned using DAMASCL program with proper criteria.
A pilot study using the image data described in Chapter 3 has shown promising results of
this method (Table 4.2). The accuracy of this method for the selected cell line T-47D is about
85%. However, the accuracy declines to 60-70% when applying to other cell lines. The
inconsistency between DAMASCL and manual assignment of SCL may be due to the
heterogeneity of the cells in the same image.
Table 4.2 Consistency between SCL patterns for 96 proteins in T47D cell line determined
with visual inspection and DAMASCL automated assignment.

DAMASCL

N
C
B
U
Sub total

N
6
0
7
0
13

Visual Inspection
C
B
0
0
72
0
7
2
0
0
79
2

U
0
2
0
0
2

Sub total
6
74
16
0
96

Discussion
DAMA staining is a novel technique with broad applications in protein expression and SCL
profiling of both cultured cell lines and tissue samples. It has been applied to comparative studies
of two tissue samples from breast cancer patients. Three proteins were identified to have
differential expression levels in the two tissue samples. By extending the scale of antibody arrays
to include 400 antibodies, more proteins can be examined in one experiment. Using Array-400,
the SCL patterns of 400 proteins were surveyed in 5 normal and cancer prostate cell lines. At
least one protein, GRK2, was confirmed to have altered SCL between normal and cancer cell
lines. Automatic assignment of SCL patterns from molecular images obtained by DAMA staining
was developed. Current assigning accuracy was limited to about 80%.
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Figure 4.4 Schema of DAMASCL program to estimate the colocalization information of
images obtained using DAMA staining. The program first extracts intensity information from
RGB images (pink box and arrows). The extracted intensity information is an array of integer
values ranging from 0 to 255 for each channel. In this schema, these arrays are represented by
the histogram of each channel, with the upper one showing green and lower one showing blue
channel. After intensity extraction, the normalization of intensity was performed for each channel
to eliminate the background or extremely high intensity pixels (green box and arrows). The
effects of different normalization strategies are under investigation. The pixels were then
subdivided into three groups based on the normalized intensity values of both channels. The
various coefficients were then calculated by the program. By comparing the coefficients with a
certain criteria, a prediction of the SCL pattern was made for that protein. This process was
repeated for each image until all the images specified have been evaluated.
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Figure 4.5 Representative images demonstrating the use of colocalization for automatic SCL assignment with DAMASCL
program. a, molecular images of three proteins showing representative SCL patterns as compared to the nuclei marker DAPI. Images
were obtained by the automatic image-taken system after DAMA staining experiment. Images in the first and second column are the
grayscale intensity distribution patterns of the target proteins (first) and DAPI (second) captured by a CCD camera. Each pair of
images was then incorporated into two separate channels of a RGB image (green for the target proteins, blue for DAPI) by the imaging
program. The resultant superimposed, pseudo-colored images (third column) can be used to visually examine the relative localizations
of the target proteins and DAPI, with protein A completely colocalizing, protein B localizing exclusively and protein C partially
colocalizing with DAPI. Images in the fourth column plot the intensity values of each pixel in the green channels against that in the
blue channels, with the red line showing the linear regression of these data. b, the various coefficients and predicted results of images
in a analyzed by DAMASCL. The predicted SCL patterns for protein A, B and C are “N”, “C” and “B”, consistent with results of
visual inspection. “NaN” represents data that cannot be calculated, such as a number divided by zero.
80

One challenge with applying DAMA staining to tissue samples is the complexity of data
analysis due to the heterogeneity of tissue samples. One solution is to obtain homogeneous
samples with technologies such as laser capture microdissection, which permitted accurate
separation of normal cells, stromal and tumor within a single specimen (Emmert-Buck et al.
1996; Bonner et al. 1997). Another possible solution may be to combine the DAMA staining
with other IHC methods (e.g. Haematoxylin and Eosin staining), and develop more sophisticated
programs to register protein expression or SCL to cell subcategories.
We have constructed the scale of 400 antibodies per array, and arraying thousands of
antibodies per membrane is also achievable. Increase of array scale is mainly limited by the
availability of high quality antibodies. Currently, most of the antibodies we used are purchased
from commercial companies. All the antibodies are characterized and demonstrated to bind their
targets in various assays before immobilized on arrays, which requires a lot of effort. The
increase in the scale of DAMA can also bring new challenges to the experimental protocol since
there is no optimal condition for all antibodies.
In the SCL profiling studies of breast (Chapter 3) and prostate cell lines, we determined the
SCLs of proteins by visual inspection of their molecular images. This manual annotation of
images is labor intensive and tends to involve subjective bias, especially when certain patterns
are expected. A logical extension of this work in high throughput study is to develop a program
for automatic assignment of SCL pattern in the images. One strategy is to obtain images of single
cell and then use the machine learning methods (e.g. pattern recognition) for automatic
assignment (Boland et al. 1998; Roques and Murphy 2002; Murphy 2005). Since the molecular
images of DAMA staining normally contain 10 to 40 cells, this strategy may not be a suitable
choice. Moreover, SCL studies using DAMA staining technology so far involve multiple cell
lines, the predicting accuracy of such pattern recognition methods may suffer since the moment
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features in different cell lines may vary. Another strategy is to use the quantitative colocalization
information of the target proteins and selected organelle markers. Early quantitative estimates of
the colocalization degree were realized by using binary masks of both channels of a dual-color
image (Lynch et al. 1991) or calculating the Pearson’s correlation coefficient (PC) of the two
images as an index of overlap (Manders et al. 1992). However, due to the ambiguity of
interpretation of negative PC values, the Manders group further developed their method to
suggest other coefficients estimating the colocalization degree better, namely overlap coefficient
and manders colocalization coefficients m1 and m2 (Manders et al. 1993). These coefficients
were widely used for the colocalization analysis since then.
Several programs have been developed to calculate these values. Despite their powerful
function to read image files and perform statistical/mathematical calculation to report these
coefficients, the existing programs have some limitation when applied to analyze images from
DAMA staining experiments. First, some programs require the signals be stored in two separate
image files, and then read each to perform the calculation. The automatic image-taken system
stores the images of target proteins and localization probes in separate channels of a RGB image
file, similar to most other current fluorescent microscopes control programs. To estimate the
colocalization coefficients using these programs, researchers will have to manually split the RGB
file into separate grayscale images which holds the information of each channel. Second, some
programs do not provide the options to preprocess to images, like subtracting backgrounds,
selecting region of interests etc. Thus, the researchers have to find other programs to perform
these tasks. Third, most of the existing programs deal with only one merged image at a time; the
researchers have to choose the original images each time if more than one image needs to be
estimated. DAMASCL is designed to accommodate the large numbers of images produced with
DAMA staining. It allows various preprocessing of images. The assigning accuracy with the
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breast cancer cell line images is not ideal because of the heterogeneity of cells. Efforts have been
initiated to obtained homogenous molecular images which have only one SCL pattern per image.
With more homogenous samples, the assignment accuracy is expected to be over 95%.

Summary
DAMA staining is a novel technique for global protein expression and SCL profiling. We
have demonstrated the application of this technique in tissue samples to compare protein
expression patterns and found 3 proteins with altered expression in two breast tissue samples. We
have also extended the scale of antibody array to 400 antibodies per array and utilized Array-400
to survey SCL profile of these 400 proteins in normal and cancer prostate cell lines. Five proteins
have been identified as having different SCL patterns between normal and cancer cell lines, but
only one have been confirmed so far. In addition, a program called DAMASCL was developed
for the automatic assignment of SCL by analyzing the quantitative colocalization information of
target proteins and organelle markers in molecular images.
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CHAPTER FIVE:
GENERAL DISCUSSION
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Dissociable antibody microarray (DAMA) staining is a novel microarray based technique
that allows large numbers of miniaturized immunostaining of proteins to occur in parallel. This
technique permits global determination of protein expression and SCL in cultured cells and tissue
samples. We have further developed DAMA staining technique by optimizing the experimental
conditions, and by designing and implementing data analysis methods in software. We have
applied DAMA staining technique to investigate the expression and SCL profiles of hundreds of
proteins in normal and cancer breast cell lines. By comparing the expression patterns of proteins
between normal and cancer breast cell lines, we have identified and confirmed five proteins with
increased expression in cancer breast cell lines, which can serve as potential biomarker for the
diagnosis of breast cancer, although further validation is necessary (Chapter 2). Preliminary IHC
results from commercial breast tissue microarrays have shown promising outcome of using some
of these proteins as diagnosis biomarkers (Song, unpublished results). However, larger sample
size (more tissues) is necessary for further validation. By comparing the SCL patterns of proteins,
we identified one protein Cyclin B1 with altered SCL in normal and cancer breast cell lines, and
confirmed this result with classic individual immunostaining (Chapter 3). DAMA staining was
also demonstrated to be applicable to tissue samples, and three proteins with differential
expression in two breast specimens were identified and confirmed (Chapter 4). Extension of
array size to 400 and application in SCL profiling of prostate cell lines have confirmed at least
one protein with altered SCL patterns in normal and cancer prostate cell lines (Chapter 4).
Further investigation was underway for identifying and confirming more targets.
Protein microarrays especially antibody microarrays are useful platforms and have been
widely used for monitoring protein expression profiles on grand scales (Haab et al. 2001; Jona
and Snyder 2003; Hall et al. 2007). Most of these antibody microarrays including DAMA are
semi-quantitative (Falk et al. 2007). The expression levels of the target proteins reported from
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those microarrays cannot transcribe to the exact amounts of proteins expressed in the samples
unless a standard curve is available for the protein of interest. Generally, these relative
expression levels are used in comparative studies to identify protein expression fluctuations
among various samples. Absolute quantification of proteins requires target-specific assays that
are currently not available in proteomic scale, and is therefore low throughput. In contrast,
reverse phase protein microarray (RPPM) technology provides an alternative form for absolute
quantification of protein expression in high throughput manner. This platform measures the
expression of one single protein in multiple samples together with the standard references whose
protein concentration is known. By comparing the signal levels of the protein in certain samples
to the signals of standard curve from standard references, the absolute expression level of the
protein in the samples can be determined (Sheehan et al. 2005; Zhang et al. 2009).
The unique advantage of DAMA staining technology is its capability to study the SCLs
(SCLs) of hundreds even thousands of proteins. There are two major strategies for visualizing
protein SCLs: immunostaining and tagging proteins with recombinant cloning technique. Results
from immunostaining are relatively static comparing to that from tagging proteins with
recombinant cloning technique. While the intracellular trafficking of tagged proteins can be
tracked under microscope in real time, immunostaining only provides a snapshot of the cellular
events at a given time point. In order to study the dynamic changes of protein SCL with
immunostaining, samples from multiple time points are required. Nonetheless, the tags of
proteins may cause mis-localization of proteins by mechanisms such as altering their localization
signal sequence (e.g. NLS) or three dimensional conformations (Lisenbee et al. 2003; Davis
2004). Moreover, recombinant cloning-tagged proteins are generally overexpressed than
endogenous proteins, which may also result in SCL patterns that are not presented by
endogenous proteins. Another way to study protein SCL is by “fractionate and identify” strategy.
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This method is also static meaning it can only observe the SCL profile of proteins at a certain
time point. One of the disadvantages of using this method is that it is impossible to purify an
organelle to 100% homogeneity and therefore it is difficult to distinguish a contaminant to other
organelles from a real SCL pattern in multiple organelles (Yates et al. 2005).
In the expression profiling study of breast cell lines using DAMA staining technology, we
examined expression of the whole cell population in the spots stained by certain antibodies. The
intercellular variations may be of interest in some cases. For example, it may be of interest to
determine whether the expression of proteins varies over the different cell cycle stages. Instead
of sampling synchronized cells at different cell cycle stages for population effect (a commonly
used strategy), we can use unsynchronized cells with DAMA staining to determine single cell
expression difference. A promising way to achieve this with unsynchronized cells is by
investigating the fluorescent signals of the proteins from single cells under high resolution
microscope and registering the cells to certain category based on their status. The cell status can
be determined by the use of cell cycle stage markers including bromo-2-deoxyuridine (BrdU)
incorporation and histone H3 phosphorylation (Gasparri et al. 2006). The same strategy may be
applied to SCL variation exploration in cell populations with heterogeneous status such as
unsynchronized cells or even tissue samples.
One challenge confronting DAMA staining technology for proteome-wide expression and
SCL study is to enlarge the scale of the antibody arrays. Increasing the scale of antibody arrays is
limited by the paucity of high quality and specific antibodies, which is a major hurdle of any
antibody-based technology for proteomic exploration. Antibodies are key components of the
adaptive immune system to recognize and bind to foreign substances or antigens. Conventional
production of antibodies involves the injection of an immunogen into an animal. Two major
types of antibodies exist: monoclonal and polyclonal antibodies. Production of monoclonal
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antibodies in large scale is a time consuming and expensive process that involves the generation
and screening of hybridomas with correct specificity. In contrast, polyclonal antibodies are
generated from antiserum that contains a mixture of antibodies recognizing different epitopes on
the antigen. Though not providing as high specificity as monoclonal antibodies, polyclonal
antibodies may be useful in applications when both native and denatured forms of antigens are to
be recognized. More recently, different strategies have been developed for the high throughput
production of antibodies. One of them is to produce recombinant antibody fragments (Fc, Fab etc)
using phage display technology as described in the Sanger “Atlas of protein expression” project
(Schofield et al. 2007). Another effort called “the Human Antibody Initiative” produced the
monospecific affinity-purified antibodies in animals by immunization of protein fragments with
unique amino acids sequence that has lowest similarity to all other human proteins (Agaton et al.
2004; Lindskog et al. 2005; Nilsson et al. 2005).
As a general rule, antibodies should be validated before their use in protein microarrays.
Ideally, any antibody to be used should show a single band by western blotting in the samples to
be examined so that any finding resulted can be attributed to the specific target protein. Most
antibody microarrays collect antibodies from commercial databases. However, a recent article
reported that only approximately half of the commercially available antibodies present a single
band on western blotting (Gulmann et al. 2006). Moreover, the antibodies that show single band
in one cell line may bind to multiple antigens in other cell lines due to mechanisms such as
alternative splicing, post-translational modification and conservative protein domains. Therefore,
it is advisable to use alternative antibodies to confirm the findings from antibody microarrays in
addition to the same antibody used in arrays. Increasing the scale of DAMA can also bring new
challenges to the staining protocol since the optimal conditions for fixation, permeabilization,
and antibody binding specificity and affinity to antigen vary from antibody to antibody.
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With the continued use of DAMA staining, large numbers of molecular images will
accumulate. There will be a need to construct a database for sharing information in the
community. We have designed a database model iDAMA to be used with ChipView program, for
holding the images and information related to them, including array type, sample and
experimental conditions, capture parameters, physical storage location of raw image files, and
SCL pattern (Fig 5.1).
The images stored in the database are in JPEG format, which provides several benefits. First,
it saves a lot of disk space. The raw image files of a 400 protein array with only one image
captured takes up 1.60 GB of the disk space, while the database of the same content but now as
JPEG images only occupies 107MB, about one sixteenth of the raw. JPEG format is a more
compressed format to store image files than the TIFF format. Although some information is lost
during the compression, we found the SCL patterns shown in the images were not changed.
Second, it improves the portability of the databases, which makes sharing of data more
convenient and efficient. Third, it speeds up the program displaying the images and thus
accelerates the procedure for visual analysis of SCL pattern. This model also took the
quantitative analysis of SCL pattern and expression profile into consideration. By storing a link
to the raw images, this database model will allow future programs to access the raw images and
obtain the intensity data stored within the image files. The annotated representative images of
proteins in various cell lines and tissue samples can be selected for web-based sharing among the
community. We are also redesigning our model as a XML database model so that other
researchers may extend this model to meet their specific needs.

Conclusion
DAMA staining technology offers a novel platform for global study of protein expression
and SCL in an automated fashion. This technology will be useful in broad applications including
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disease biomarker discovery, molecular mechanism exploration and carcinoma classification and
characterization. The image management and analysis programs developed in parallel with this
technology will also be applicable to various high throughput immunostaining-based
technologies. In the future, we can expect a localization and expression atlas of proteins in
various organisms generated from data of DAMA staining and other technologies to be shared in
the scientific community.

Figure 5.1 Structural schema of iDAMA image database model. The relational database
consist of a main table holding images and related information, and several other tables linked to
the main table or one another with detailed information about certain aspects.
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